<SEC-DOCUMENT>0000950170-24-035366.txt : 20240322
<SEC-HEADER>0000950170-24-035366.hdr.sgml : 20240322
<ACCEPTANCE-DATETIME>20240322161544
ACCESSION NUMBER:		0000950170-24-035366
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240322
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240322
DATE AS OF CHANGE:		20240322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		24775427

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acet-20240322.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-22T15:44:32.9952+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:acet="http://www.adicetbio.com/20240322" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_da0d9fe3-cf8d-48aa-8a90-24c87e1fe408" name="dei:EntityCentralIndexKey" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0">0001720580</ix:nonNumeric><ix:nonNumeric id="F_09cf4c6a-fcf1-4718-a0fe-dba5cf7ce909" name="dei:AmendmentFlag" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0">false</ix:nonNumeric><ix:nonNumeric id="F_85ae9203-5b14-43af-88bc-ee17b61c1993" name="dei:SecurityExchangeName" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0">NONE</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acet-20240322.xsd"/></ix:references><ix:resources><xbrli:context id="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68b28bb0-fb15-4548-b8a0-314b37d41e8b" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_dba60b6f-0145-452c-9b32-44597aaf0c01" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 22, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2de8f9cc-9a1c-46c5-89c4-3e9512c72f38" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4fd3161d-fd49-43d4-a040-23e0a0dd012a" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_738ce428-b8a9-468a-a430-dd6ce23c8775" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-38359</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_82a73381-9dd4-4d15-8d70-736c561abbb9" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-3305277</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_70ae38c6-b915-4949-82a7-c5e23d58ff01" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131 Dartmouth Street, Floor 3</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2397e0ee-3d03-4bca-a967-6abf6d388bd5" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_b2cb106d-0075-4223-8615-9db85a8335cd" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_895dffb2-aaee-4435-998c-fe255216fb57" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02116</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_e80cce5a-35c6-4a11-8d7e-0deb6e3d2db4" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_712d8990-4cd5-42b2-ac40-2d58eeafbd58" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">503-9095</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c47a0e7a-e634-43c7-8cd5-8085e715d768" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Not applicable</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d0492de-75e6-483e-89f7-d74397cf0d80" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e1e1710-307f-4eb6-8591-e3de0fcf8b4d" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20dccd33-303f-45eb-a593-a488cdba83f7" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2623bc65-696e-4b4c-9574-99be5485d795" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b901163e-fd9d-43fa-931b-d41b4fcd4c8d" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_524053c3-795c-466f-a1c9-80cd81ae627f" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ACET</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_85ae9203-5b14-43af-88bc-ee17b61c1993;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Market</span></span></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_3808d418-fdf4-4609-9592-44ead2f873b7" contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1.01 Entry into a Material Definitive Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 22, 2024, Adicet Bio, Inc. (the &#8220;Company&#8221;) entered into an Open Market Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), from time to time, through an &#8220;at the market&#8221; equity offering program under which Jefferies will act as sales agent or principal.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, Jefferies may sell the shares (a) in privately negotiated transactions with the consent of the Company; (b) as block transactions; or (c) by any other method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, including sales made through The Nasdaq Global Market or any other trading market for our common stock. In addition, Jefferies may also sell shares to Jefferies acting as principal for Jefferies&#8217; own account. Jefferies will use its commercially reasonable efforts in conducting sales activities consistent with its normal trading and sales practices. Jefferies and the Company each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party&#8217;s sole discretion at any time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Sales Agreement provides that Jefferies will be entitled to compensation for its services an amount equal to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. Jefferies and the Company have no obligation to sell any shares under the Sales Agreement and may at any time suspend any sale under the Sales Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-263587), filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on March 15, 2022, as amended, and declared effective by the Commission on May 9, 2022, as supplemented by a prospectus supplement, filed with the Commission on March 22, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing description of the material terms of the Sales Agreement is qualified in its entirety by reference to the full agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The legal opinion of Goodwin Procter LLP relating to the shares of Common Stock that may be sold pursuant to Sales Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:2%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex1_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Open Market Sales Agreement</span><span style="color:#0000ff;top:-4.6899999999999995pt;white-space:pre-wrap;text-decoration:underline;font-size:6.7pt;position:relative;min-width:fit-content;">SM</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">, dated as of March 22, 2024, by and between the Company and Jefferies LLC</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex5_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Opinion of Goodwin Procter LLP</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex5_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Goodwin Procter LLP (included in Exhibit 5.1)</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.96%;"/>
    <td style="width:4.58%;"/>
    <td style="width:6.28%;"/>
    <td style="width:44.18%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ADICET BIO, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 22, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nick Harvey</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Name:</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Nick Harvey</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Title:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>acet-ex1_1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<html>
 <head>
  <title>EX-1.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">OPEN MARKET SALE AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">March 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">JEFFERIES LLC <br>520 Madison Avenue</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">New York, New York 10022</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Common Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), on the terms set forth in this agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  DEFINITIONS</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Certain Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following respective meanings:</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#x201c;control&#x201d; (including the terms &#x201c;controlling,&#x201d; &#x201c;controlled by&#x201d; and &#x201c;under common control with&#x201d;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agency Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y) the date this Agreement is terminated pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Commission</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Floor Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent&#x2019;s sole discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Issuance Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Issuance Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> that is executed by its Chief Executive Officer, President or Chief Financial Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Issuance Notice Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 3(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Issuance Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Sales Price less the Selling Commission.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Maximum Program Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Common Shares with an aggregate Sales Price of the lesser of (a) the number or dollar amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#x2019;s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable), or (d) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or other entity of any kind.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Principal Market</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Global Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sales Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Selling Commission</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means three percent (3%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Settlement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the second business day, or such other time period as required by the Exchange Act or by the rules promulgated thereunder, following each Trading Day during the period set forth in the applicable Issuance Notice on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Common Shares issued or issuable pursuant to this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Trading Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any day on which the Principal Market is open for trading.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  REPRESENTATIONS AND WARRANTIES OF THE COMPANY </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company represents and warrants to, and agrees with, the Agent that, unless such representation, warranty or agreement specifies otherwise, as of (1) the date of this Agreement, (2) each Issuance Notice Date, (3) each Settlement Date, (4) each Triggering Event Date (as defined below) with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) and (5) each Time of Sale (each of the times referenced above is referred to herein as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Representation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company has prepared and filed with the Commission a shelf registration statement on Form S-3 (File No. 333-263587) that contains a base prospectus (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Such registration statement registers the issuance and sale by the Company of the Shares under the Securities Act.  The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Shares, including pursuant to Rule 462(b) under the Securities Act (any such registration statement filed pursuant to Rule 462(b), a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 462(b) Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act as from time to time amended or supplemented, is herein referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act, in each case, as from time to time amended or supplemented, is referred to herein as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use.  The Registration Statement at the time it originally became effective is herein called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Original Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;  As used in this Agreement, the terms &#x201c;amendment&#x201d; or &#x201c;supplement&#x201d; when applied to the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All references in this Agreement to financial statements and schedules and other information which is &#x201c;contained,&#x201d; &#x201c;included&#x201d; or &#x201c;stated&#x201d; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date; and all references in this Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be incorporated by reference in or otherwise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date. The Company&#x2019;s obligations under this Agreement to furnish, provide or deliver or make available (and all other references of like import) copies of any report or statement shall be deemed satisfied if the same is filed with the Commission through its Electronic Data Gathering Analysis and Retrieval system (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EDGAR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">At the time the Registration Statement was or will be originally declared effective and at the time the Company&#x2019;s most recent annual report on Form 10-K was filed with the Commission, if later, the Company met the then-applicable requirements for use of Form S-3 under the Securities Act.  During the Agency Period, each time the Company files an annual report on Form 10-K the Company will meet the then-applicable requirements for use of Form S-3 under the Securities Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Registration Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Original Registration Statement and any Rule 462(b) Registration Statement have been declared effective by the Commission under the Securities Act.  The Company has complied to the Commission&#x2019;s satisfaction with all requests of the Commission for additional or supplemental information.  No stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. The Company meets the requirements for use of Form S-3 under the Securities Act specified in FINRA Conduct Rule 5110(h)(1)(C).</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	The Prospectus when filed complied in all material respects with the Securities Act and, if filed with the Commission through EDGAR (except as may be permitted by Regulation S&#x2011;T under the Securities Act), was identical to the copy thereof delivered to the Agent for use in connection with the issuance and sale of the Shares.  Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto, at the time it became effective and at all subsequent times, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.  As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered together (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Time of Sale Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The Prospectus, as amended or supplemented, as of its date and at all subsequent times, did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  below.  There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ineligible Issuer Status</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. As of the date of this Agreement, the Company is not an &#x201c;ineligible issuer&#x201d; in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act.  Any Free Writing Prospectus (as defined below) that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act.  Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein.  Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to the Agent before first use, the Company has not prepared, used or referred to, and will not, without the Agent&#x2019;s prior consent, prepare, use or refer to, any Free Writing Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incorporated Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable, and, when read together with the other information in the Prospectus, do not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other information in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at each Time of Sale (as defined below), as the case may be, will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#x2019;s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company&#x2019;s most recent fiscal </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">quarter; and (iii) are effective in all material respects to perform the functions for which they were established.  Since the end of the Company&#x2019;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#x2019;s internal control over financial reporting (whether or not remediated) and no change in the Company&#x2019;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting.  The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement has been duly authorized, executed and delivered by the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Authorization of the Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Applicable Registration or Other Similar Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subsequent to the respective dates as of which information is given in the Registration Statement or the Prospectus, except as disclosed therein, (i) the Company has not declared or paid any dividends, or made any other distribution of any kind, on or in respect of its capital stock, (ii) there has not been any material change in the capital stock or long-term or short-term debt of the Company or its subsidiaries listed on Exhibit 21.1 of its most recent Annual Report on Form 10-K (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), (iii) there have been no transactions entered into by the Company or the Subsidiaries which are material with respect to the Company and the Subsidiaries, taken as a whole, other than in the ordinary course of business, (iv) neither the Company nor any Subsidiary has sustained any material loss or interference with its business or properties from fire, explosion, flood, earthquake, hurricane, accident or other calamity, whether or not covered by insurance, or from any labor dispute or any legal or governmental proceeding, and (v) there has not been any material adverse change, or any development involving a prospective material adverse change, whether or not arising from transactions in the ordinary course of business, in or affecting the business, management, condition (financial or otherwise), results of operations, stockholders&#x2019; equity, properties or prospects of the Company and the Subsidiaries, taken as a whole (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Since the date of the latest balance sheet included, or incorporated by reference, in the Registration Statement or the Prospectus, neither the Company nor any Subsidiary has incurred or undertaken any liabilities or obligations, whether direct or indirect, liquidated or contingent, matured or unmatured, or entered into any transactions, including any acquisition or disposition of any business or asset, which are material to the Company and the Subsidiaries, taken as a whole, except for liabilities, obligations and transactions which are disclosed in the Registration Statement and the Prospectus.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Independent Accountants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  KPMG LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement or the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PCAOB</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The financial statements, including the notes thereto, and the supporting schedules included or incorporated by reference in the Registration Statement and the Prospectus present fairly in all material respects the consolidated financial position as of the dates indicated and the cash flows and results of operations for the periods specified of the Company and the Subsidiaries; said financial statements have been prepared in conformity with United States generally accepted accounting principles (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) applied on a consistent basis throughout the periods involved; and the supporting schedules, if any, included in the Registration Statement and the Prospectus present fairly in all material respects in accordance with GAAP the information required to be stated therein.  No other historical or pro forma financial statements or supporting schedules are required to be included in the Registration Statement or the Prospectus by the Securities Act, the Exchange Act or the rules and regulations promulgated thereunder.  The other financial and statistical information included or incorporated by reference in the Registration Statement and the Prospectus present fairly in all material respects the information included therein and have been prepared on a basis consistent with that of the financial statements that are included or incorporated by reference in the Registration Statement and the Prospectus and the books and records of the respective entities presented therein.  All disclosures contained in the Registration Statement and the Prospectus, or incorporated by reference therein, regarding &#x201c;non-GAAP financial measures&#x201d; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s Accounting System</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company and the Subsidiaries maintain a system of internal accounting and other controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management&#x2019;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, (iii) access to assets is permitted only in accordance with management&#x2019;s general or specific authorization, (iv) the recorded accounting for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto. </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating to the Company and the Subsidiaries is made known to the Company&#x2019;s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective. The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by the Company&#x2019;s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.  The Company&#x2019;s internal control over financial reporting is effective and, except as disclosed in the Registration Statement and the Prospectus, the Company is not aware of any material weaknesses in its internal control over financial reporting.  Since the date of the latest audited financial statements included or incorporated by reference in the Prospectus, there has been no change in the Company&#x2019;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incorporation and Good Standing of the Company and its Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company and each Subsidiary has been duly organized and validly exists as a corporation, partnership or limited liability company (as the case may be) in good standing under the laws of its jurisdiction of organization and has corporate, partnership or limited liability company power and authority (as the case may be) to own or lease its property and conduct its business as described in the Registration Statement and the Prospectus.  The Company and each Subsidiary is qualified to do business and is in good standing as a foreign corporation, partnership or limited liability company (as the case may be) in each jurisdiction in which the character or location of its properties (owned, leased or licensed) or the nature or conduct of its business makes such qualification necessary, except for those failures to be so qualified or in good standing which (individually and in the aggregate) could not reasonably be expected to have a material adverse effect on (i) the business, management, condition (financial or otherwise), results of operations, stockholders&#x2019; equity, properties or prospects of the Company and the Subsidiaries, taken as a whole; or (ii) the ability of the Company to consummate the Offering or any other transaction contemplated by this Agreement or the Registration Statement and the Prospectus (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The certificate or articles of incorporation, by-laws, partnership agreement, limited liability company agreement or other constitutive and organizational documents (as the case may be) of the Company and the Subsidiaries comply with the requirements of applicable law and are in full force and effect.  The Subsidiaries are the only &#x201c;subsidiaries&#x201d; of the Company (within the meaning of Rule 405 under the Securities Act.) </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Capitalization and Other Capital Stock Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company has an authorized capitalization as set forth in the Prospectus, and all of the issued and outstanding shares of capital stock of the Company are fully paid and non-assessable and have been duly authorized and validly issued, in compliance with all applicable state, federal and foreign securities laws and not in violation of or subject to any preemptive or similar right that entitles any person to acquire from the Company or the Subsidiaries any Common Stock or other security of the Company or any security convertible into, or exercisable or exchangeable for, Common Stock or any other such </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">security of the Company (any &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Relevant Security</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except for such rights as may have been fully satisfied or waived prior to the effectiveness of the Registration Statement.  All of the issued shares of capital stock of or other ownership interests in the Subsidiaries owned, directly or indirectly, by the Company have been duly authorized and validly issued and are fully paid and non-assessable and are owned directly or indirectly by the Company free and clear of any lien, charge, mortgage, pledge, security interest, claim, equity, trust or other encumbrance, preferential arrangement, defect or restriction of any kind whatsoever (any &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Exchange Listing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and have been approved for listing on the Nasdaq Global Market (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to completion of the issuance of the Shares pursuant to this Agreement, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing.  To the Company&#x2019;s knowledge, it is in compliance with all applicable listing requirements of Nasdaq.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the Company nor any Subsidiary (i) is in violation of its certificate or articles of incorporation, by-laws, certificate of formation, limited liability company agreement, partnership agreement or other organizational documents, (ii) is in default under, and no event has occurred which, with notice or lapse of time or both, would constitute a default under or result in the creation or imposition of any Lien upon any property or assets of the Company or the Subsidiaries pursuant to, any indenture, mortgage, deed of trust, note, lease, loan agreement or other agreement or instrument to which it is a party or by which it is bound or to which any of its property or assets is subject, or (iii) is in violation of any statute, law, rule, regulation, ordinance, directive, judgment, writ, decree or order of any court or judicial, regulatory or other legal or governmental agency or body, foreign or domestic, having jurisdiction over the Company or the Subsidiaries except (in the case clauses (ii) and (iii) above) for violations or defaults that could not (individually or in the aggregate) reasonably be expected to have a Material Adverse Effect. The Company and the Subsidiaries have all requisite power and authority, and all necessary consents, approvals, authorizations, orders, registrations, qualifications, licenses, filings and permits of, with and from all judicial, regulatory and other legal or governmental agencies and bodies and all third parties, foreign and domestic (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), to own, lease and operate its properties and conduct its business as it is now being conducted and as disclosed in the Registration Statement and the Prospectus, and each such Consent is valid and in full force and effect, except in each case as could not reasonably be expected to have a Material Adverse Effect.  Neither the Company nor any Subsidiary has received notice of any investigation or proceedings which, if decided adversely to the Company or the Subsidiaries, could reasonably be expected to result in the revocation of, or imposition of a materially burdensome restriction on, any such Consent. The issue and sale of the Offered Securities (including the use of proceeds from the sale of the Offered Securities as described in the Registration Statement and the Prospectus), the compliance by the Company with this Agreement and the consummation of the transactions contemplated hereby and by the Registration Statement and the Prospectus do not and will not (i) conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default (or an event which with notice or lapse of time, or both, would constitute a default) under, or result in the creation or imposition of any Lien upon any property or assets of the Company or the Subsidiaries pursuant </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to, any indenture, mortgage, deed of trust, note, lease, loan agreement or other agreement, instrument, franchise, license or permit to which the Company or any Subsidiary is a party or by which the Company or the Subsidiaries or their respective properties, operations or assets may be bound, (ii) violate or conflict with any provision of the certificate or articles of incorporation, by-laws, certificate of formation, limited liability company agreement, partnership agreement or other organizational documents (as the case may be) of the Company or the Subsidiaries, or (iii) violate or conflict with any statute, law, rule, regulation, ordinance, directive, judgment, writ, decree or order of any court or judicial, regulatory, administrative or other legal or governmental agency or body (including, without limitation, the U.S. Food and Drug Administration (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), domestic or foreign, having jurisdiction over the Company or the Subsidiaries, except (in the case of clauses (i) and (iii) above) as could not reasonably be expected to have a Material Adverse Effect. No Consent is required for the execution, delivery and performance by the Company of this Agreement, the issue and sale of the Shares (including the use of proceeds from the sale of the Shares as described in the Registration Statement and the Prospectus) and the consummation by the Company of the transactions contemplated hereby and by the Registration Statement and the Prospectus, except the registration under the Securities Act of the Shares, such Consents as may be required by Nasdaq in regards to the listing of the Shares and under applicable state securities or blue sky laws and such other Consents as have been obtained.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company and the Subsidiaries (i) are in material compliance with all statutes, rules and regulations applicable to the testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company or the Subsidiaries (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) except where such noncompliance could not reasonably be expected to have a Material Adverse Effect, (ii) have not received any Form 483 from the FDA, notice of adverse finding, warning letter, or other written correspondence or notice from the FDA, the European Medicines Agency (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EMA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the U.K. Medicines and Healthcare Products Regulatory Agency (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MHRA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the German Federal Institute for Drugs and Medical Devices (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BfArM</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Authorizations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), that could, individually or in the aggregate, result in a Material Adverse Effect; (iii) possess all material Authorizations and such Authorizations are valid and in full force and effect and neither the Company nor any Subsidiary is in material violation of any term of any such Authorizations except where such nonpossession, failure or noncompliance could not reasonably be expected to have a Material Adverse Effect; (iv) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA, the EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any Company product, operation or activity is in material violation of any Applicable Laws or Authorizations which noncompliance could reasonably be expected to have a Material Adverse Effect and has no knowledge that the FDA, the EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding against the Company; (v) have not received written notice that the FDA, EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">revoke any material Authorizations that could reasonably be expected to have a Material Adverse Effect and has no knowledge that the FDA, EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority is considering such action; and (vi) have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations, except whether the failure to file, obtain, maintain or submit such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments could not result in a Material Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission) except such incompletions and incorrections as could not reasonably be expected to result in a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Material Actions or Proceedings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  There is no judicial, regulatory, arbitral or other legal or governmental proceeding or other litigation or arbitration, domestic or foreign, pending to which the Company or any Subsidiary is a party or of which any property, operations or assets of the Company or the Subsidiaries is the subject which, individually or in the aggregate, if determined adversely to the Company or any Subsidiary, could reasonably be expected to have a Material Adverse Effect on the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder; to the Company&#x2019;s knowledge, no such proceeding, litigation or arbitration is threatened or contemplated; and the defense of all such proceedings, litigation and arbitration against or involving the Company or any Subsidiary could not reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company and its Subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent rights, licenses, approvals, inventions, copyrights, domain names, technology, trade secrets, know-how (including unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property and similar rights, including registrations and applications for registration thereof (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) necessary or material to the conduct of the business now conducted or proposed in the Registration Statement and the Prospectus to be conducted by them, and the failure to own, possess or acquire such Intellectual Property Rights and the expected expiration of any such Intellectual Property Rights would not, individually or in the aggregate, have a Material Adverse Effect. To the Company&#x2019;s knowledge, none of the patents and patent applications owned or licensed by the Company or its Subsidiaries is invalid or unenforceable, in whole or in part. To the Company&#x2019;s knowledge, none of the Intellectual Property Rights owned or licensed by the Company or its Subsidiaries, other than patents and patent applications, are invalid or unenforceable, in whole or in part. To the knowledge of the Company, there are no unreleased liens or security interests which have been filed against any of the Intellectual Property Rights owned or licensed by the Company. Except as disclosed in the Registration Statement and the Prospectus, (i) the Company is not obligated to pay a material royalty, grant a license or provide other material consideration to any third party in connection with the Intellectual Property Rights owned by or licensed to the Company; (ii) to the Company&#x2019;s knowledge, there are no rights of third parties to any of the Intellectual Property Rights owned by or licensed to the Company or its Subsidiaries, in any field of use, other than the respective licensor to the Company of such Intellectual Property Rights; (iii) to the Company&#x2019;s knowledge, there is no material infringement, misappropriation breach, default or other violation, </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or the occurrence of any event that with notice or the passage of time would constitute any of the foregoing, by the Company or its Subsidiaries of any third party Intellectual Property Rights or third parties of any of the Intellectual Property Rights of the Company or its Subsidiaries; (iv) there is no pending or, to the Company&#x2019;s knowledge, threatened action, suit, proceeding or claim by others against the Company or its Subsidiaries or, to the Company&#x2019;s knowledge against any person or entity, (a) challenging the Company&#x2019;s or any of its Subsidiaries&#x2019; rights in or to, or the violation of any of the terms of, any of their Intellectual Property Rights; (b) challenging the validity, enforceability or scope of any such Intellectual Property Rights; or (c) that alleges the Company or any of its Subsidiaries infringes, misappropriates or otherwise violates or conflicts with any Intellectual Property Rights or other proprietary rights of others, and, in each case, the Company is unaware of any facts which would form a reasonable basis for any such claim; (v) none of the Intellectual Property Rights owned by or licensed to the Company or its Subsidiaries in their businesses has been obtained or is being used by the Company or its Subsidiaries in violation of any contractual obligation binding on the Company or any of its Subsidiaries in violation of the rights of any persons; and (vi) to the Company&#x2019;s knowledge, no employee or consultant of the Company or any of its Subsidiaries is in or has ever been in violation of any term of any employment or consulting contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer or consultant where the basis of such violation relates to such employee&#x2019;s employment with or such consultant&#x2019;s services to the Company or any of its Subsidiaries or actions undertaken by the employee or consultant while employed with or providing services to the Company or any of its Subsidiaries. To the knowledge of the Company and as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (1) neither the commercial development nor the sale of any of the proposed products or processes of the Company, as described in the Registration Statement and the Prospectus, infringes, misappropriates or otherwise violates, or would, upon the commercialization of such proposed products or processes, infringe, misappropriate or otherwise violate, any Intellectual Property Rights of any third party; and (2) each current and former employee and consultant of the Company (a) has executed an inventions assignment and confidentiality agreement with the Company, on or about the respective date of hire, and signed copies of such agreements have been made available to the Agent and its counsel; and (b) has signed or agreed to assign to the Company any and all Intellectual Property Rights he or she may possess or may have possessed that are related to the Company&#x2019;s business, as currently conducted and as proposed to be conducted, as described in the Registration Statement and the Prospectus. All patents and patent applications owned by or licensed to the Company or under which the Company has rights have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">USPTO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and any similar office or agency in the world in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO or similar office or agency that were not disclosed and which would preclude the grant of a patent in connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title to Properties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company and its Subsidiaries do not own any real property and have good title to all other properties owned by them, free and clear of any and all Liens except such as (A) are described in the Registration Statement and the Prospectus or (B) do not </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(individually or in the aggregate) materially affect the value of such property or materially interfere with the use made or proposed to be made of such property by the Company and the Subsidiaries; and any real property and buildings held under lease or sublease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material to, and do not materially interfere with, the use made and proposed to be made of such property and buildings by the Company and the Subsidiaries.  Neither the Company nor any Subsidiary has received any notice of any claim adverse to its ownership of any real or personal property or of any claim against the continued possession of any real property, whether owned or held under lease or sublease by the Company or the Subsidiaries.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(w)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Law Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as would not reasonably be expected to result in a Material Adverse Effect, the Company and each Subsidiary has accurately prepared and timely filed all federal, state, foreign and other tax returns that are required to be filed by it or have been granted extensions thereof and has paid or made provision for the payment of all taxes, assessments, governmental or other similar charges, including without limitation, all sales and use taxes and all taxes which the Company or any Subsidiary is obligated to withhold from amounts owing to employees, creditors and third parties, with respect to the periods covered by such tax returns (whether or not such amounts are shown as due on any tax return).  Except as would not reasonably be expected to result in a Material Adverse Effect, no  deficiency assessment with respect to a proposed adjustment of the Company&#x2019;s or the Subsidiaries&#x2019; federal, state, local or foreign taxes is pending or, to the Company&#x2019;s knowledge, threatened.  The accruals and reserves on the books and records of the Company and the Subsidiaries in respect of tax liabilities for any taxable period not finally determined are adequate to meet any assessments and related liabilities for any such period and, since December 31, 2020, except as would not reasonably be expected to have a Material Adverse Effect, the Company and the Subsidiaries have not incurred any liability for taxes other than in the ordinary course of its business.  There is no tax lien, whether imposed by any federal, state, foreign or other taxing authority, outstanding against the assets, properties or business of the Company or the Subsidiaries, other than any such tax lien arising automatically under applicable law with respect to taxes not yet due and payable or being contested in good faith.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company and the Subsidiaries maintain insurance in such amounts and covering such risks as the Company reasonably considers adequate for the conduct of its business and the value of its properties and as is customary for companies engaged in similar businesses in similar industries, all of which insurance is in full force and effect, except where the failure to maintain such insurance could not reasonably be expected to have a Material Adverse Effect.  There are no material claims by the Company or the Subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause.  The Company reasonably believes that it will be able to renew its existing insurance as and when such coverage expires or will be able to obtain replacement insurance adequate for the conduct of the business and the value of its properties at a cost that could not have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(y)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Environmental Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  There has been no storage, generation, transportation, handling, use, treatment, disposal, discharge, emission, contamination, release or other activity involving any kind of hazardous, toxic or other wastes, pollutants, contaminants, petroleum products or other hazardous or toxic substances, chemicals or materials (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Hazardous Substances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by, due to, on behalf of, or caused by the Company or the Subsidiaries (or, to the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s knowledge, any other entity for whose acts or omissions the Company is or may be liable) upon any property now or previously owned, operated, used or leased by the Company or the Subsidiaries, or upon any other property, which would be a violation of or give rise to any liability under any applicable law, rule, regulation, order, judgment, decree or permit, common law provision or other legally binding standard relating to pollution or protection of human health and the environment (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Environmental Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except for violations and liabilities which, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect.  There has been no disposal, discharge, emission, contamination or other release of any kind at, onto or from any such property or into the environment surrounding any such property of any Hazardous Substances with respect to which the Company or any Subsidiary has knowledge, except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Company&#x2019;s knowledge, there are no events or circumstances that would reasonably be expected to form the basis for an order for cleanup or remedial action, except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.  There is no pending or, to the Company&#x2019;s knowledge, threatened administrative, regulatory or judicial action, claim or notice of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any Subsidiary, except in each case which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.  No property of the Company or any Subsidiary is subject to any Lien under any Environmental Law.  Neither the Company nor any Subsidiary is subject to any order, decree, agreement or other individualized legal requirement related to any Environmental Law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(z)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Labor and Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No labor disturbance by the employees of the Company or the Subsidiaries exists or, to the Company&#x2019;s knowledge, is imminent and the Company is not aware of any existing or imminent labor disturbances by the employees of any of its or the Subsidiaries&#x2019; principal suppliers, manufacturers&#x2019;, customers or contractors, which, in either case (individually or in the aggregate), could reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(aa)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ERISA Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) each &#x201c;employee benefit plan&#x201d; (within the meaning of Section 3(3) of the Employee Retirement Security Act of 1974, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) for which the Company or any member of its &#x201c;Controlled Group&#x201d; (defined as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) would have any liability (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has been maintained in compliance with its terms and with the requirements of all applicable statutes, rules and regulations including ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii) with respect to each Plan subject to Title IV of ERISA (A) no &#x201c;reportable event&#x201d; (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably expected to occur, (B) no &#x201c;accumulated funding deficiency&#x201d; (within the meaning of Section 302 of ERISA or Section 412 of the Code), whether or not waived, has occurred or is reasonably expected to occur, (C) the fair market value of the assets under each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan), and (D) neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation in the ordinary course and without </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">default) in respect of a Plan (including a &#x201c;multiemployer plan&#x201d;, within the meaning of Section 4001(c)(3) of ERISA); and (iv) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(bb)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company Not an &#x201c;Investment Company.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  The Company is not and, at all times up to and including consummation of the transactions contemplated by this Agreement, and after giving effect to application of the net proceeds of the Offering as described in the Prospectus, will not be, required to register as an &#x201c;investment company&#x201d; under the Investment Company Act of 1940, as amended, and is not and will not be an entity &#x201c;controlled&#x201d; by an &#x201c;investment company&#x201d; within the meaning of such act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(cc)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Price Stabilization or Manipulation; Compliance with Regulation M</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the Company nor any of its affiliates (within the meaning of Rule 144 under the Securities Act) has taken, directly or indirectly, any action which constitutes or is designed to cause or result in, or which could reasonably be expected to constitute, cause or result in, the stabilization or manipulation of the price of any security to facilitate the sale or resale of the Offered Securities or to result in a violation of Regulation M under the Exchange Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Regulation M</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(dd)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Related-Party Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. To the Company&#x2019;s knowledge, no relationship, direct or indirect, exists between or among any of the Company or any affiliate of the Company, on the one hand, and any director, officer, shareholder, customer or supplier of the Company or any affiliate of the Company, on the other hand, which is required by the Securities Act or the Exchange Act to be described in the Registration Statement or the Prospectus that is not so described as required.  There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of the Company or any of their respective family members.  The Company has not, in violation of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sarbanes-Oxley Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), directly or indirectly, including through any affiliate of the Company, extended or maintained credit, arranged for the extension of credit, or renewed an extension of credit, in the form of a personal loan to or for any director or executive officer of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ee)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FINRA Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  All of the information provided to the Agent or to counsel for the Agent by the Company and, to the Company&#x2019;s knowledge, its officers, directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Offered Securities is true, complete and correct in all material respects and compliant with Financial Industry Regulatory Authority, Inc.&#x2019;s (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FINRA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) rules and, to the Company&#x2019;s knowledge, any letters, filings or other supplemental information provided to FINRA pursuant to FINRA rules or NASD Conduct Rules is true, complete and correct in all material respects.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ff)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Statistical and Market-Related Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  All statistical, demographic and market&#x2011;related data included in the Registration Statement or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects.  To the extent required, the Company has obtained the written consent to the use of such data from such sources.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(gg)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sarbanes-Oxley Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. There is and has been no failure on the part of the Company or any of the Company&#x2019;s directors or executive officers, in their capacities as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act, including Section 402 related to loans and Sections 302 and 906 related to certifications.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(hh)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Unlawful Contributions or Other Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the Company nor any of its subsidiaries nor, to the best of the Company&#x2019;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any applicable law or of the character required to be disclosed in the Registration Statement or the Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Anti-Corruption and Anti-Bribery Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the Company nor any of its subsidiaries, nor any director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof); (ii) made, offered, promised or authorized any direct or indirect unlawful payment; or (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or the rules and regulations thereunder, the Bribery Act 2010 of the United Kingdom or any other applicable anti-corruption, anti-bribery or related law, statute or regulation (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Anti-Corruption Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); the Company and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of Anti-Corruption Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(jj)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and the anti-money laundering laws of the various jurisdictions in which the Company and its subsidiaries conduct business, (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(kk)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the Company nor any of its subsidiaries, nor any director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is (i) currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or the U.S. Department of State and including, without limitation, the designation as a &#x201c;specially designated national&#x201d; or &#x201c;blocked person,&#x201d; the European Union, His Majesty&#x2019;s Treasury, the United Nations Security Council, or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">other relevant sanctions authority (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), (ii) organized or resident in a country or territory that is the subject or target of comprehensive Sanctions (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sanctioned Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any unlawful activities of or business with any person that, at the time of such funding, is the subject or the target of Sanctions, or in any country or territory, that, at the time of such funding, is a Sanctioned Jurisdiction or (ii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; neither the Company nor any of its subsidiaries is knowingly engaged in, or has, at any time in the past five years, knowingly engaged in, any dealings or transactions with or involving any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the subject or target of Sanctions or with any country or territory that was or is, as applicable, at the time of such dealing or transaction, a Sanctioned Jurisdiction; the Company and its subsidiaries have instituted, and maintain, policies and procedures designed to promote and achieve continued compliance with Sanctions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ll)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Brokers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  There are no contracts, agreements or understandings between the Company and any person that would give rise to a valid claim against the Company or the Agent for a brokerage commission, finder&#x2019;s fee or other like payment in connection with the transactions contemplated by this Agreement or, to the Company&#x2019;s knowledge, any arrangements, agreements, understandings, payments or issuance with respect to the Company or any of its officers, directors, shareholders, partners, employees, subsidiaries or affiliates that may affect the Agent&#x2019;s compensation, as determined by FINRA Rule 5110.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(mm)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Material Lending Relationships</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company (i) does not have any material lending or other relationship with any bank or lending affiliate of the Agent and (ii) does not intend to use any of the proceeds from the sale of the Shares to repay any outstanding debt owed to any affiliate of the Agent.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(nn)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each financial or operational projection or other &#x201c;forward-looking statement&#x201d; (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement or the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward&#x2011;looking statement.  No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(oo)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cybersecurity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company and its subsidiaries&#x2019; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IT Systems</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, to the knowledge of the Company, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and administrative controls, policies, procedures, and safeguards designed to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#x201c;Personal Data,&#x201d; used in connection with their businesses. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Personal Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as applicable, (i) a natural person&#x2019;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&#x2019;s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as &#x201c;personally identifying information&#x201d; under the Federal Trade Commission Act, as amended; (iii) &#x201c;personal data&#x201d; as defined by the European Union General Data Protection Regulation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GDPR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); (iv) any information which would qualify as &#x201c;protected health information&#x201d; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">HIPAA&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">); and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#x2019;s health or sexual orientation. To the knowledge of the Company, there have been no material breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(pp)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Data Privacy Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. To the knowledge of the Company, the Company and its subsidiaries are, and for the past three years were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance with, GDPR (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Privacy Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company and its subsidiaries have made all disclosures to users or customers required by applicable Privacy Laws, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. To the knowledge of the Company, neither it nor any subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(qq)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Clinical Data and Regulatory Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The pre-clinical and clinical studies (as applicable) conducted by, on behalf of or sponsored by the Company or its Subsidiaries, or in </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">which the Company or its Subsidiaries or their product candidates participated, including, to the knowledge of the Company, such studies conducted by Novartis International Pharmaceutical Ltd. or its affiliates, were and, if still pending are being, conducted in all material respects in accordance with standard medical and scientific research procedures and with all applicable local, state and federal laws, rules and regulations, including, without limitation, the Federal Food, Drug and Cosmetic Act and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312; the descriptions of the results of such studies contained in the Registration Statement and the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies; the Company is not aware of any studies, the results of which are inconsistent with or otherwise call into question the study results described or referred to in the Registration Statement or the Prospectus; and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing pre-clinical studies or clinical investigations conducted or proposed to be conducted by or on behalf of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(rr)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance Programs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company has established and administers a compliance program applicable to the Company, to assist the Company and the directors, officers and employees of the Company in complying with applicable regulatory guidelines (including, without limitation, those administered by the FDA, the EMA, the MHRA, the BfArM, and any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA or EMA); except where such noncompliance could not reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ss)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Health Care Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company and each of its Subsidiaries has operated and currently is in compliance in all material respects with all applicable Health Care Laws (as defined below), including, without limitation, the rules and regulations of the FDA, the U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare &amp; Medicaid Services, the Office for Civil Rights, the Department of Justice or any other governmental agency or body having jurisdiction over the Company or any of its activities, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. For purposes of this Agreement, &#x201c;Health Care Laws&#x201d; shall mean the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Physician Payment Sunshine Act (42 U.S.C. &#167; 1320a-7h), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Act (42 U.S.C. &#167; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under HIPAA, the exclusion laws (42 U.S.C. &#167; 1320a-7), the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.), the patient privacy, data security and breach notification provisions under HIPAA, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 262 et seq.), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), the regulations promulgated pursuant to such laws, and any other similar local, state or federal law and regulations. The Company has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence, communication or notice from the FDA or any other governmental or regulatory authority alleging or asserting noncompliance with any Health Care </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Laws applicable to the Company. The Company is not a party to nor has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Neither the Company, its Subsidiaries nor any of their respective employees, officers, directors or, to the Company&#x2019;s knowledge, consultants has been excluded, suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or, to the Company&#x2019;s knowledge, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(tt)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Underwriting Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company is not a party to any agreement with an agent or underwriter for any other &#x201c;at the market&#x201d; or continuous equity transaction.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 4(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  ISSUANCE AND SALE OF COMMON SHARES</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sale of Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Mechanics of Issuances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(i)  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Issuance Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 5(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 5(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance Notice; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that (A) in no event may the Company deliver an Issuance Notice to the extent that (I) the sum of (x) the aggregate Sales Price of the requested Issuance Amount, plus (y) the aggregate Sales Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B) prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by e&#x2011;mail to the persons set forth in Schedule A hereto and confirmed by the Company by telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(ii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agent Efforts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice, the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement.  For the avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time provided they both agree in writing to any such modification.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(iii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Method of Offer and Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Shares may be offered and sold (A) in privately negotiated transactions with the consent of the Company; (B) as block transactions; or (C) by any other method permitted by law deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Principal Market or sales made into any other existing trading market of the Common Shares.  Nothing in this Agreement shall be deemed to require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clauses (A) and (B) above) the method of placement of any Shares by the Agent shall be at the Agent&#x2019;s discretion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(iv)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Confirmation to the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of Shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(v)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Settlement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent or its designee&#x2019;s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement Date.  The Company may sell Shares to the Agent as principal at a price agreed upon by the parties at each relevant time Shares are sold pursuant to this Agreement (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Time of Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(vi)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Suspension or Termination of Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and the period set forth in any applicable Issuance Notice shall immediately terminate; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that (A) such suspension and termination shall not affect or impair either party&#x2019;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice; (B) if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 3(b)(v)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> with respect to such Shares; and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable legal fees and expenses), as</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">21</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v) above, and may use the Shares to settle or close out such borrowings.  The Company agrees that no such notice shall be effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 3(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(vii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Guarantee of Placement, Etc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in placing Shares; (B) the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares; and (C) the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(viii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Material Non-Public Information.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is in possession of material non-public information.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3(b)(vi))</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> by the Agent deducting the Selling Commission from the applicable Issuance Amount.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Shares; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares; (iv) all fees and expenses of the Company&#x2019;s counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below) prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, attorneys&#x2019; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing and printing a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Blue Sky Survey</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or memorandum and a &#x201c;Canadian wrapper&#x201d; and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions; (vii) the reasonable fees and disbursements of the Agent&#x2019;s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#x2019;s participation in the offering and distribution of the Shares; (viii) the filing fees incident to FINRA review, if any; (ix) the costs and expenses of the Company relating to investor presentations on any &#x201c;road show&#x201d; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">22</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the cost of any aircraft chartered in connection with the road show; and (x) the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent&#x2019;s counsel pursuant to subsections (vi) and (vii) above shall not exceed (A) $75,000 in connection with the execution of this Agreement, (B) $25,000 in connection with each Triggering Event Date (as defined below) involving the filing of a Form 10-K on which the Company is required to provide a certificate pursuant to Section 4(o) and (C) $15,000 in connection with each other Triggering Event Date on which the Company is required to provide a certificate pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4(o</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">).</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  ADDITIONAL COVENANTS</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Agency Period, the Company shall (i) file, on a timely basis, with the Commission all reports and documents required to be filed under</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act; and (ii) either, in the Company&#x2019;s sole discretion, (A) include in its quarterly reports on Form 10-Q and its annual reports on Form 10-K, a summary detailing, for the relevant reporting period, (1) the number of Shares sold through the Agent pursuant to this Agreement and (2) the net proceeds received by the Company from such sales or (B) prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interim Prospectus Supplement&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, such summary information and, at least once a quarter and subject to this Section 4, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities Act)).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities Act Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission in relation to the Registration Statement or the Prospectus; (ii) of the time and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or any Free Writing Prospectus; (iii) of the time and date that any post-effective amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective; and (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.  If the Commission shall enter any such stop order at any time, the Company will use its reasonable best efforts to obtain the lifting of such order at the earliest possible moment.  Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">23</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendments and Supplements to the Prospectus and Other Securities Act Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company agrees (subject to Sections 4(d) and 4(f)) to promptly prepare, file with the Commission (including by filing a document incorporated by reference therein) and furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act.  Neither the Agent&#x2019;s consent to, or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#x2019;s obligations under Sections 4(d) and 4(f).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, the Company shall not be required to file such amendment or supplement if there is no pending Issuance Notice and the Company believes that it is in its best interest not to file such amendment or supplement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agent&#x2019;s Review of Proposed Amendments and Supplements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prior to amending or supplementing the Registration Statement (including any registration statement filed under Rule 462(b) under the Securities Act) or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement insofar as such proposed amendment or supplement relates to the transactions contemplated in this Agreement, and the Company shall not file or use any such proposed amendment or supplement without the Agent&#x2019;s prior consent, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Use of Free Writing Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Neither the Company nor the Agent has prepared, used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#x2019;s prior written consent, any &#x201c;written communication&#x201d; that constitutes a &#x201c;free writing prospectus&#x201d; as such terms are defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Free Writing Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Free Writing Prospectuses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed Free Writing Prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed Free Writing Prospectus or any amendment or supplement thereto without the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">24</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agent&#x2019;s consent, which shall not be unreasonably withheld, conditioned or delayed.  The Company shall furnish to the Agent, without charge, as many copies of any Free Writing Prospectus prepared by or on behalf of, or used by the Company, as the Agent may reasonably request.  If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any Free Writing Prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such Free Writing Prospectus to eliminate or correct such conflict or so that the statements in such Free Writing Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that prior to amending or supplementing any such Free Writing Prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented Free Writing Prospectus and the Company shall not file, use or refer to any such amended or supplemented Free Writing Prospectus without the Agent&#x2019;s consent, which shall not be unreasonably withheld, conditioned or delayed.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Filing of Agent Free Writing Prospectuses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company shall not take any action that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a Free Writing Prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Copies of Registration Statement and Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  After the date of this Agreement through the last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and each amendment thereto, and with copies (which may be electronic copies) of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule 424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable); and if the Company decides to amend or supplement the Registration Statement or the Prospectus as then amended or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">25</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance, including filing a document incorporated by reference therein (it being acknowledged that the Company may delay the filing of any amendment or supplement if, in the judgment of the Company, it is in the best interest of the Company); provided, however, that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Blue Sky Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares.  The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.  The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Earnings Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Listing; Reservation of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  (a)  The Company will maintain the listing of the Shares on the Principal Market; and (b) the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Due Diligence</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.   During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during normal business hours and at the Company&#x2019;s principal offices or virtually, as the Agent may reasonably request from time to time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i) </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">26</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">an affirmation to the Agent that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto); and (ii) an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Deliverables at Triggering Event Dates; Certificates.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> The Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		(A)	the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to Section 4(a)(ii)(B)), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration Statement or Prospectus;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		(B)	the filing with the Commission of an annual report on Form 10-K or a quarterly report on Form 10-Q (including any Form 10-K/A or Form 10-Q/A containing amended financial information or a material amendment to the previously filed annual report on Form 10-K or quarterly report on Form 10-Q), in each case, of the Company; or</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		(C)	the filing with the Commission of a current report on Form 8-K of the Company containing amended financial information (other than information &#x201c;furnished&#x201d; pursuant to Item 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) that is material to the offering of securities of the Company in the Agent&#x2019;s reasonable discretion;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(any such event, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Triggering Event Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Company shall furnish the Agent (but in the case of clause (C) above only if the Agent reasonably determines that the information contained in such current report on Form 8-K of the Company is material) with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A) confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B) that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 5(a)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, and (C) containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">27</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this Section 4(o), then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this Section 4(o) dated as of the date that the instructions for the sale of Shares are issued.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Legal Opinions.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, a negative assurances letter and the written legal opinion of Goodwin Procter LLP, counsel to the Company and Squire Patton Boggs (US) LLP, intellectual property counsel to the Company, each dated the date of delivery, in form and substance reasonably satisfactory to Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such Triggering Event Date). </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agents Counsel Legal Opinion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Agent shall have received from Duane Morris LLP, counsel for the Agent, such opinion or opinions, on or before the date on which the delivery of the Company counsel legal opinion is required pursuant to Section 4(p), with respect to such matters as the Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they reasonably request for enabling them to pass upon such matters.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Comfort Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause KPMG LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required on the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus.  If requested by the Agent, the Company shall also cause a comfort letter to be furnished on the date of the occurrence of any material transaction or event requiring the filing of a current report on Form 8-K containing material amended financial information of the Company, including the restatement of the Company&#x2019;s financial statements. The Company shall be required to furnish no more than one comfort letter hereunder per calendar quarter. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(r)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Secretary&#x2019;s Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date, the Company shall furnish the Agent a certificate executed</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by the Secretary of the Company, signing in such capacity, dated the date of delivery (i) certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii) certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii) containing any other certification that the Agent shall reasonably request.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agent&#x2019;s Own Account; Clients&#x2019; Account</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company consents to the Agent trading, in compliance with applicable law, in the Common Shares for the Agent&#x2019;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investment Limitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Market Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall use commercially reasonable efforts to cause each of its Affiliates to, comply with all applicable provisions of Regulation M.  If the limitations of Rule 102 of Regulation M (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 102</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section (d) of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall use commercially reasonable efforts to cause each of its Affiliates to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d) of Rule 102. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice of Other Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, during the period beginning on the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice; and will not directly or indirectly enter into any other &#x201c;at the market&#x201d; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement; provided, however, that such restrictions will not be required in connection with the Company&#x2019;s (i) issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or vesting and settlement of restricted stock units or other equity awards pursuant to any </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">29</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">employee or director stock option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (ii) issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, (iii) issuance, grant or sale of Common Shares or securities convertible into Common Shares as consideration for mergers, acquisitions, other business combinations, joint ventures, strategic alliances and other business transactions (including, without limitation, collaborations or arrangements involving research, development and/or commercialization activities) occurring after the date of this Agreement which are not used primarily for capital raising purposes; provided that in the case of this clause (iii), such issuances shall not be greater than 5% of the total outstanding shares of the Company immediately following the issuance of such shares, and (iv) modification of any outstanding options, warrants or any rights to purchase or acquire Common Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions:</font></div></div>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Accuracy of the Company&#x2019;s Representations and Warranties; Performance by the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company shall have delivered the certificate required to be delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> on or before the date on which delivery of such certificate is required pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company shall have performed, satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 4(p)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4(q)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4(r)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Injunction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">30</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#x201c;nationally recognized statistical rating organization&#x201d; as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Suspension of Trading in or Delisting of Common Shares; Other Events</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The trading of the Common Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Principal Market or any of their constituent markets.  There shall not have occurred (and be continuing in the case of occurrences under clauses (i) and (ii) below) any of the following:  (i) trading or quotation in any of the Company&#x2019;s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities generally on the Principal Market shall either have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or FINRA; (ii) a general banking moratorium shall have been declared by any of federal or New York, authorities; or (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#x2019; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Documents Required to be Delivered on each Issuance Notice Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Agent&#x2019;s obligation to use its commercially reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate as required to be delivered pursuant to Section 4(o) (which certificate shall not be required if the foregoing representations shall be set forth in the Issuance Notice).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Misstatement or Material Omission</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Agent shall not have advised the Company that the Registration Statement, the Prospectus or the Times of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#x2019;s reasonable opinion is material, or omits to state a fact that in the Agent&#x2019;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">31</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  INDEMNIFICATION AND CONTRIBUTION</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="ole_link2"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification of the Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; or (iii) any act or failure to act or any alleged act or failure to act by the Agent in connection with, or relating in any manner to, the Common Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i) or (ii) above, provided that the Company shall not be liable under this clause (iii) to the extent that a court of competent jurisdiction shall have determined by a final judgment that such loss, claim, damage, liability or action resulted directly from any such acts or failures to act undertaken or omitted to be taken by the Agent through its bad faith or willful misconduct, and to reimburse the Agent and each such </font><font id="ole_link1"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">officer, employee and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">controlling person for any and all expenses (including the reasonable and documented fees and disbursements of counsel chosen by the Agent) as such documented expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in subsection (b) below.  The indemnity agreement set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  shall be in addition to any liabilities that the Company may otherwise have.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Company, its Directors and Officers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">32</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; but, for each of (i) and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information set forth in the first sentence of the ninth paragraph under the caption &#x201c;Plan of Distribution&#x201d; in the Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and all expenses (including the fees and disbursements of one counsel chosen by the Company) as such expenses are reasonably incurred by the Company or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this Section 6(b) shall be in addition to any liabilities that the Agent or the Company may otherwise have.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notifications and Other Indemnification Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Promptly after receipt by an indemnified party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or to the extent it is not prejudiced as a proximate result of such failure.  In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties.  Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#x2019;s election so to assume the defense of such action and approval by the indemnified party of </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">33</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">counsel, the indemnifying party will not be liable to such indemnified party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Agent (in the case of counsel for the indemnified parties referred to in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6(a)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">above)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or by the Company (in the case of counsel for the indemnified parties referred to in Section 6(b) above), (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Settlements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The indemnifying party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment.  Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request; and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.  No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Contribution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If the indemnification provided for in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement; or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.  The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">34</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent.  The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties&#x2019; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, any reasonable and documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.  The provisions set forth in Section 6(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Section 6(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> that no additional notice shall be required with respect to any action for which notice has been given under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> for purposes of indemnification.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="here"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Notwithstanding the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Agent shall not be required to contribute any amount in excess of the agent fees received by the Agent in connection with the offering contemplated hereby.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.  For purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, each officer and employee of the Agent and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  TERMINATION &amp; SURVIVAL</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the term of this Agreement shall continue from the date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination; Survival Following Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i) 	Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement, upon ten (10) Trading Days&#x2019; notice to the other party; provided that, (A) if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">35</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company shall remain obligated to comply with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 3(b)(v)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> with respect to such Shares and (B) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> shall survive termination of this Agreement.  If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.</font></p>
  <p style="margin-left:10%;text-indent:-3.846%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii) In addition to the survival provision of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 7(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any termination of this Agreement.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  MISCELLANEOUS</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Press Releases and Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may issue a press release describing the material terms of the transactions contemplated hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form 8&#x2011;K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation,  any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Advisory or Fiduciary Relationship</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company acknowledges and agrees that (i) the transactions contemplated by this Agreement, including the determination of any fees, are arm&#x2019;s-length commercial transactions between the Company and the Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) the Agent has not assumed nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv) the Agent and its respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (v) the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">36</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Research Analyst Independence</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company acknowledges that the Agent&#x2019;s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and as such the Agent&#x2019;s research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions.  The Company understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows:</font></div></div>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If to the Agent:</font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>Jefferies LLC<br>520 Madison Avenue<br>New York, NY 10022<br>Facsimile: (646) 619-4437<br>Attention:  General Counsel</font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">with a copy (which shall not constitute notice) to:</font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>Duane Morris LLP</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1540 Broadway</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">New York, NY 10036</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attention: Dean M. Colucci</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Email:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Adicet Bio, Inc.</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">131 Dartmouth Street, 3rd Floor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Boston, MA 02116</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attention: Nick Harvey</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Email:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">with a copy (which shall not constitute notice) to:</font></p>
  <p style="margin-left:3.333%;text-indent:-7.407%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>Goodwin Procter LLP</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">100 Northern Avenue</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Boston, MA 02210</font></p>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attention:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">37</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:10%;text-indent:-8%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Email:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 8(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, and in each case their respective successors, and no other person will have any right or obligation hereunder.  The term &#x201c;successors&#x201d; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Partial Unenforceability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof.  If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.  Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Related Proceedings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Specified Courts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Related Judgment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.  Service of any process, summons, notice or document by mail to such party&#x2019;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.  The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recognition of the U.S. Special Resolution Regimes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. (i) In the event that the Agent is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. (ii) In the event that the Agent is a Covered Entity and the Agent or a BHC Act Affiliate of such Agent becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">38</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As used in this Section 8(h):</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BHC Act Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; has the meaning assigned to the term &#x201c;affiliate&#x201d; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k).</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any of the following: (i) a &#x201c;covered entity&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#x201c;covered bank&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a &#x201c;covered FSI&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Default Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">U.S. Special Resolution Regime</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.  This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com).  This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.  The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[Signature Page Immediately Follows]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">39</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Very truly yours,</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	/s/ Nick Harvey	   	</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Name: Nick Harvey</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Title:  Chief Financial Officer  	</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">JEFFERIES LLC</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: /</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">s/ Donald Lynaugh		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Name: Donald Lynaugh</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Title:  Managing Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[Signature Page to Open Market Sale Agreement]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ISSUANCE NOTICE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Date]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Jefferies LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">520 Madison Avenue</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">New York, New York 10022</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attn: [__________]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reference is made to the Open Market Sale Agreement between Adicet Bio, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Jefferies LLC (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) dated as of March 22,  2024.  The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Delivery of Issuance Notice (determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x200e;Section 3(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">): _______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Issuance Amount (equal to the total Sales Price for such Shares):</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	$</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Number of days in selling period:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">First date of selling period:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Last date of selling period:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Settlement Date(s) if other than standard T+2 settlement:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">				</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Floor Price (in no event less than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent&#x2019;s sole discretion): $ ____ per share</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Comments: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">												</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">						</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Name:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Title:  <br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice Parties</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Chen Schor</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nick Harvey</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Agent</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Donald Lynaugh</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Michael Magarro</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>acet-ex5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html>
 <head>
  <title>EX-5.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">										March 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">131 Dartmouth Street, 3rd Floor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts 02116</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Re:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities Registered under Registration Statement on Form S-3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-3 (as amended or supplemented, the &#x201c;Registration Statement&#x201d;) filed on March 15, 2022 with the Securities and Exchange Commission (the &#x201c;Commission&#x201d;) pursuant to the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), relating to the registration of the offering by Adicet Bio, Inc., a Delaware</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">corporation (the &#x201c;Company&#x201d;), of up to $500,000,000 of any combination of securities of the types specified therein. The Registration Statement was declared effective by the Commission on May 9, 2022. Reference is made to our opinion letter dated March 15, 2022 and included as Exhibit 5.1 to the Registration Statement.  We are delivering this supplemental opinion letter in connection with the sales agreement prospectus supplement (the &#x201c;Prospectus Supplement&#x201d;) filed on March 22, 2024 by the Company with the Commission pursuant to Rule 424(b) under the Securities Act.  The Prospectus Supplement relates to the offering by the Company of up to $100,000,000 in shares (the &#x201c;Shares&#x201d;) of the Company&#x2019;s common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;) covered by the Registration Statement.  The Shares are being offered and sold by the sales agent named in, and pursuant to, a sales agreement between the Company and such sales agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of the opinion set forth below, we have assumed that the Shares are issued for a price per share equal to or greater than the minimum price authorized by the Company&#x2019;s board of directors  or a duly authorized committee of the board of directors prior to the date hereof (the &#x201c;Minimum Price&#x201d;) and that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares that may be issued for the Minimum Price.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of the opinion set forth below, we refer to the following as &#x201c;Future Approval and Issuance&#x201d;: (a) the approval by the Company&#x2019;s board of directors (or a duly authorized committee of the board of directors) of the issuance of the Shares (the &#x201c;Approval&#x201d;) and (b) the issuance of the Shares in accordance with the Approval and the receipt by the Company of the consideration (which shall not be less than the par value of such Shares) to be paid in accordance with the Approval.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The opinion set forth below is limited to the Delaware General Corporation Law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">March 22, 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon Future Approval and Issuance, will be validly issued, fully paid and nonassessable.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This opinion is being furnished to you for submission to the Commission as an exhibit to the Company&#x2019;s Current Report on Form 8-K relating to the Shares (the &#x201c;Current Report&#x201d;), which is incorporated by reference in the Registration Statement.  We hereby consent to the filing of this opinion letter as an exhibit to the Current Report and its incorporation by reference and the reference to our firm in that report.  In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Very truly yours,</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ GOODWIN PROCTER LLP</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GOODWIN PROCTER LLP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acet-20240322.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-22T15:44:33.9218+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adicetbio.com/20240322" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acet="http://www.adicetbio.com/20240322" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acet-20240322.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140436894041376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 22,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">131 Dartmouth Street, Floor 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">503-9095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not applicable<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NONE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /.!=E@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #S@798'BMRCN\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NDT'AZC+96BG(2$Q"<0M2KPMHDFCQ*C=V].&K1."!^ 8^\_G
MSY);'83N(S['/F DB^EN=)U/0H<U.Q$% 9#T"9U*Y93P4_/01Z=H>L8C!*4_
MU!&!5]4#."1E%"F8@458B$RV1@L=45$?+WBC%WSXC%V&&0W8H4-/">JR!B;G
MB>$\=BW< #.,,+KT74"S$'/U3VSN +LDQV27U# ,Y=#DW+1##6]/NY>\;F%]
M(N4U3K^2%70.N&;7R:_-YG&_99)7?%543<'YGE>BOA?-ZGUV_>%W$W:]L0?[
MCXVO@K*%7W<AOP!02P,$%     @ \X%V6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M2P$"% ,4    " #S@798'BMRCN\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #S@798F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( /.!=E@1I(+^@ 0  %01   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #S@798GZ ;\+$"  #B#
M#0              @ '$#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /.!
M=EB7BKL<P    !,"   +              "  : /  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( /.!=E@ZJJ+G0 $  #P"   /              "  8D0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #S@798)!Z;HJT   #X 0  &@
M            @ 'V$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #S@79899!YDAD!  #/ P  $P              @ ';$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   E%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="acet-20240322.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  acet-20240322.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="acet-20240322.htm">acet-20240322.htm</File>
    <File>acet-20240322.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "acet-20240322.htm": {
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20240322",
   "dts": {
    "inline": {
     "local": [
      "acet-20240322.htm"
     ]
    },
    "schema": {
     "local": [
      "acet-20240322.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20240322.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20240322.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adicetbio.com/20240322/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-24-035366-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-035366-xbrl.zip
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M6P ,P(A,HE!F3$#I*$XQ*UW"+<O[+*".7WK-J8BXP(T@@(;$"C89HK\:3(B
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M5\2[_<KMVJ\\JCL1'W_ZX:C>3P?!I_\'4$L#!!0    ( /.!=ECLT<BWIP@
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M?QIT"K(IKY]]<_+--]_^U\7O<$HNXW2:U,$/:1$&K_+I21A$P8LDB^ZB,@E
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M+^%,8\39O[Q93/"3,HB++(O*(.+D(5SBWQ]NFE8UZ0M&!U 2<S839,Y[^EK
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M@&TBQN] M5!4>_<MRA1\<A@=AGRF( V<>B.K!Z<1,9D>Z-%_*^]P<!;@B=D
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MCK8,!#R?"GT=H?CWASYT/D@.X7'#B!<WD(J328T=?Q6!I4T41#;1 ;9QL6&
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M/-,:%60SCLG-KWZLOQN3FV-R<V1UWO%L#4G1(_Q_!^C@O$^RY!;Y$,5071V
M:[..&PT]"*O-6?-7" W7H &SI4E+0H7+>JT'UM98"FS9MTW6V")&?6(0A7TJ
MBGDG56W85#P%+,$6UF39RF65R%9AFP+H/H:+<8$VVT.4%\&!#(RC/8P9=F*B
ML%N6@$TB*94LQ8ZR&&9"CID%V'LW$?YKF24Q_M><!9T1N#B+TD5H0AUU"6?:
MSF&2@]<X$<J=I21%:HK-E"7:$^RIQLE,^#CPIJ6-4RHK5W 'YE)5))AK.-2#
M]Q-,W@&<M3'OLD-_]-<'[8^R;6[RXS\Q1'3O?J<5OIX/P<A?IQ39\OI>2V/O
ML_.C"86PX1\W)NC4 P!0&4M0UUN!?&8"D2U8B+^)JCCZ-?@Q*R8@CUY'Y4?P
M<0^QH(\'>@"B)70=W#4=HH>[K;<I4S5.Z(8B.."=%XI-=A [(><R-&=-ZVS-
M 7AN2)"3-(]JBZUP"66]@0TT22(J6=TKSN7DC?-:A,1+-9= J X>J1;)5&'B
MJMJF3-PFZ4[#;]F!7#(FL7=ZJ/,.W9IXNY/Q/ W C!"$)$H[K26-M2$$HJ_<
M#LOR*$>ULD.U4CYHM?(&S$_",<+QR_5<76D!PJL<=BJG"BZPZ/5E4Y(IZ'';
M4R+LDH0S5B6\ETK6O:JF-]O1SV$*D<^3%_TCAMC[IVZ\G\P" SW<*GLSD/EQ
M7)B!'(YRD]!K@/$=-5G-XC#41CL)KJW?.X:2M=PVGL3;E-XRBY;,)TE]3^$#
M.+AX%>5K358)\[+>@\38Q[^5';=,C(!+%VUR/+2N@V99Y!)9%>2 +8GI!CD[
MGIJCB;AS/1_AIO2<G3@1T@%T9:A':"*I=/A/@8'R[D1['Z7F!*"2$FYD$L+,
M"42# W_,_692-)1SL[^@EYCY. FO $AT<2CYX/YM28%><(4;>HGH+J3RE-"I
M>PV%&Y1<- G'WL(_?VGB&^FB "X?3LL4?4;J1D#K)ZV)BJ:DMX;K4TR8FWL7
MY<I.4#^;*LQW/N7I*&+P'C7DCBJX@(,+>RQ$+8]RQ8>PW+8.:M]R2\SAR+ O
M(W]J%C4(%*3][Y#@3.".QV0EFNFKV!*@/5LI(%5!"#YD@:$-+<3"1IS"0"KZ
M9',Q(-\@RUA7PT%)^H X-C%CB^CP0+($B%3ZAIVJ/%K@*O3,#OC3@X%4H8)*
MX%\S$%#YC4",J3:N(F.,S0S,I1#5+HRD=Y?8DL4UVR25HBK8*?I/O"%8E&7,
M;3-I)+*#J)>(;*'@"'1(QOL:(S(XG0=HYC^7I3D(0Y_A6B+W>($([9*TL4;K
MH%LLVL 2E::C<IT&MKX,'FS@7&0AR^3A\RB&IBBB7N2 "4<JY(I$ R'@M@89
M#1[>;>V(.1&VB<>@ZG0F:ND6-^Z-48>6=;I2+9S.4"*G5"+*(V"?:(-0#.4=
MA]_/5\I(VF5P9F&/:G:!PY,&!$=>80MS+XZ7L[9U%TKH#3#,&;3;ZQ!4"<EX
M;.+UR*=0:MCBD&FI;*)TPVV^"$YXS)+#\:):,54!MK2;',FO!(WEN*%>W;.'
MOD)\^(3EHCQC>]A57#!4'H.FVOP=;5:LA@:)+9PDGO45!9@[F]*G'>M!!PMB
MW=20<)E#I5NBU\H[HBTO=B2;-.LLQW ;T_%8C=1]&H]C9ONK*Z;OQ\SVF-D>
M,]L[GJW?S@L.'1\8;'+,_X%:3(S+0#8-<WD8?[<'H>0#]?N<YTU"N]#J/(?A
MRAJOH4M :)4!8UK9)9=("6M%Q<L[>E3T"2M$52,/)@ZT%9:WUXHT,8>U,[._
MR /L[!CVO=A,#,#;/A+AV)OLQ")-(2V$#!PGY.>3ZY/@)98SH%7THFQNP!>P
MS\0J@@/U-%^^N#P()],XZ##MXKA_?K@G[(WW(,+#A'QZ(CX[<OK>%*X':H@9
ME=14JHMQYTB#TY7&2NBD]S@3= C]9%D]Z#%)ANISO"3YZ9=Y1OUN3M\;_49>
MCUG\3LIOD ';>__0<TX-+FGBD&S"D#1?ETO]=J4.M\DL^W,*P^3'MX'&+J88
M14X&:UI]7%E\,8V&Y94[)IO8+B9,O#BFY7:8EJL>=%KN>2N]^Q-LIKUC/=:&
ML4DB<X6/[9C8DZ06,Z(*!X@[77*M0J(5="!#M\D:U?HU,Q ]9.K"&W^,;N@B
MDI!51?]N*C)&;'-(_!E"0^C;+)H@H1?_9E'P]RA.0VX3:SK-4D5@298TAB-*
MBCER[T7M_41<$FI 4OR4A<70D&/Y*8^LVR&[S_X]1#B+TZAXOUO44E6+\K@C
M7@:2O7F1.SOQRTT$\2/H(KZ/@Q6A7IQ/OGML-318:*$;%)9[S=)<;-*HI!*U
M+,%2HM!:MV@QP^MA73*Z/ 4*0XZVR=W\1Q#XI4&'"#RZUPG:T<A6=\G6\*':
MKU>O#\-^92_@'R?.S*%H^GL29?5\BI+M'9_L2LF ,=MUX)/[^N_O#V=V?TS0
M.@Y>2EG6*Q,21CF++A?/.,T_?/\BN4V1I?)0Y_:'V67Y^B FURO8DJJW4*O@
MD%H@<YPRWU6FV+O-W1K:!^36O-$*\ZI*F)#&*'9?HIH004L;Z,!L;MF)C/A9
M:T*N$VEM-X.M26BVI>$1EDX_@G_%RKM.3)R>C6\25>V!':0J]5[[(#:6Q4F$
MP2:,1.CEH 8TYX4X[& Q5917=EE;6Z RXSJU/P=1O#DMS-"G[;*W#+4QX^AD
MS;BI]\S93OZ(>BT.>44R*H5)@S7W;FV1"Z89[MHB:CSXV6BI\&"7'1UEC,FY
M?9#G< [I'TE.4ZH18">)#3\O)ZF#8)6 ,8=W>FR2U_(/U$;\+Y*=OXG@(L-9
M422.'..V#%Q>NW3L="=L3,/!L"45Q6S8$SVBKK4K.*C=M]Z?N]:&W"<O+";8
MXI$/8L*U94;,!"7FR,C&PTZU/;NHO2/7@"9 XB";8>T>Z@NBL=YX!OR9^JJS
M9+#PH=!SBV[%VJM<8D_PM1XB^),BU*%V7<-L3IS.:+K'G/57UXEGIV/2>DQ:
MCTGK'<\6=Y'T"4!;6M2!ZOZ6:O.K*H.6CB3]R(*?67^/;C6Z1$UI0Y,@" V;
M+P<0JV8BK2L8/XPQR2IT2P,P(U5I](E=KLR"?J5SE!3^4N)D(B5-F]RM5H?:
MK4RBT+&4C5VNMC$L([ZMOJQ]5?NB6C_U%5_3-= W>C=: H>6)D:ZO_IH[] !
M<3"<4M8GQ>$8163F/)QW(LCEIL>([J.?RB6ZN?0QLL0XD K[NZ*8,&,R 5=Z
MW32WI83"NIC+7?F3[5*T6TSVF"S;8;*L?M#)LC>%LTFF!@'TS@*M]YTZP[P8
MZ9\!> M[0I:?<@#8XGA!]LK4]9,\GZH7DH'>A+#@WQ^K!<ZO+6A2Z.T \FH+
M&&[*@"4M1%8T_,9($^'EN;!V V3>?YO-@/D-EH3(SOL!P+O]Z O3'G<-8H3J
M;B:9+&X5F#Z<%X/]")Q"8=AK))#=V,[@5N&%0-1U(I:%^P*V?2M2>^0,1#$*
MSBEG\)[ 1";V$>JVTX)B7UA%M@SOO1V >48EL3LET3QH)8%=6ZAP#.0*J@:N
M&GA/U$6'TJBECRQ=F;8EGLPU&@C9%5Y!ZFQBNE)090?B)<%.0P-OB4>Z)EI9
MZDG*5$UNN9^3A,&H6RY6Z+18KO1BT"-HA^=@:2*'<3*=YS Y-\00A$U2*L1T
MXH4H?Q[-BSL7O-;D_&@N%/M+49I/:,#<O2ZI(RXP1=AIBCNTU;TEE-XE2KHL
MC4^.90B(ZD!+&9MV3)- _N31T;"MODS=?>"1EGN<CEZG=Z]V,I"V>\9DI_RE
MAU.C7!0(R5:MX@$FG0[S5%@PARUVA3DV,0+1?P[;.?YIJA6Q2-&6)_*&67Y6
M9:)0G]N;L9I>6+(3QWVE&DO-;%$N@4\HJ<EU$VUN9A0;_",MO7S#YIO<J;;<
MQH+:6+6\C861&^"IB!G&P49N]V.Q"N]RG[N^!^_4$7R4@N%,'TD-R4BAV B9
M2[]@/E/X-UJH]Q[UVNG\G"&'RL0^C_)-<Q(*6NYS7M!&L7PC6[O1X)W! &SR
M,I&V 4@&QPWHVZQOFJAR:/LH**#VFH/V_:+Y.D%BGAUT$E+6_U8W(;&4V2A<
M1BNW=4!9K*(,_92;$FO^(J]R13H[\<(YR$6.ST6:CJ$\L)OG(H[]7+BL# WZ
M%E,T67FSY-OR%](-8/-&]E9:&!@99VY+Z'7@VZ_?VL'U;_F4"S%G:9)1D1&!
M+IUSP"AN4['#]R[*SKUGFV6<P@>VGAYVNMUV<!AQE:3V(JUL]US"N%/A;&BJ
M7HW-8+*_X9A\VT/R[6Q,OHW)MS'YMN/9DB"4,$+E%B/$5?Z4QF@5^;.I!_;X
MC26)ZA;X6X6#0<>;@F)/6]A[BK9RM.QZC56VM)U/<K#^MYW@9'LX%Z9_N]$C
M&CI%QORM5)")J WAK<CEQ32/TPZT!]_2/UW;C,(SXZ0I05%RKP(PB(ZB8V0(
MAFG*;UKQ.'LSS8#..F,PS9'$_N!DG5 [XKW6$U @XX3],"TWZ?Y)=[!D/=.K
M&.-9>BB!#)W"#;;VG[@5T_38Y.\2:O?;#5#VS(,Q+*J65>$$'K#EE!;85FZ%
M;67QLYNV.ULC;LC$&GZ\>\@Q#3TNG$[SS2;W6F]B18HZ 7R8,>H"5K(35II$
M5<IQ#A_0Q<"K>_I4][8QQ4N #:(N/M%F57[U'/VR$G:B9EL?LX=BC9IA1OP&
M-@ ?3%(Y_?GVN\*_.5G"9L'LB:R<M/]VH7T,S1>K1"NU,5F*GDU_;Y#>H>EA
MQ6DD)FZ:R[[I<-&O_%S-8<B3A0V*YLP$&IVFQ1Z3@+),@A8!3<E>GOT>R= Q
M@9S4J20-O*^J G:-U&VWONM[GDZ X2^ZQ5 .C$ (;#'M34>/=CPRG/.TEJUI
M96 OA9CH'*BK8J>*>DNSOT7?Z/K8]7-F3CE[^!B9Q]AK)8Q9#>2S^M:S4/RM
M,.$R[ZX<@('= D<^,U_&9ECL$1,PY=[CV!BA4+*P>P6KOJ!.Z^S8 X'#WEI@
M*QSD3;"5>80)KYU::D=3F=#A4JM_- !-4J@=?_FBTNOPWGJ$%.T= _2)$LE_
M2>WYI!MV_<O8Q[>?WOOP< N5U;'H1-*='XM^(M.3Y\(_@XI9&9)M:+F0[*)J
M?$HN./D+3[SP?4Q:@<I;C(@PD1NSA)(=G2!-1"MVH4VEX7V24'(&Q&8-EH88
MH SFTMN[5=[43SZZC=+,+6[% K+:)'ZF10,Z,9-9FO KRC,*X62AC<_OUVUE
M+P<LR]8OS)R;6,V9)\2)69L&'O)9HG@FXG//-,#6JZ)L'TY$^?#*$@BI111H
M=F$KN/Z%I^>$6H-L%XG>:()P]6X7($%$?S*'$?*;U)LBLDY[$.9;@X7(5AID
MA8\LI.]B\]W8 V-W!WN/$A6%P1"Z+TJKR*4'*MS9AHH;[G\SA8<7S#+J*$\9
M ?&AO)/Y@RL^:)8-F?C0&SS4JKR?K]]]>'L(F2O:[&@L2U:QX'FC4TPUH[*_
M[XHRB_O"R9TEM3B,5NR[QYPWV$P^8S;@KNN+TT0R8&AX[/\G)9=4V!L0%Z'C
M+,#L89J4[2,.L!.5I!R^GA<S+H3S<FR:&.?#L[4B+95FSB5U^?AF(IU-ESXY
M_C1Z.@+2?:=]<6=V3_:W:<:NHSM$J=P^:)3*!VPAB?OSG2$VVS=V<3TZ11A*
M$:3"KE8;54&'D!J%U_INU%[4A#*TF;8J9LZO]_>T4N/F)TIGNL!CT,M'E\Q
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M945E6<7D<<Q7,P;"=A@(FTP>="!,3:8W&$[.S4EZ14DW"M]H#P8]2GOD.O+
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M"88-)#+1E*PZW-YYZ&Y,T?50- ?]JH@MJK6<I!@/(*6G_0&VM/[[^M?U3NE
M [9A3\EIOS:JJMVIJH\?'[2JN@:AO7?X^QAL&!Q8R@$!*L?.T9*F B/AIQ%'
MMD8&9P/?KG1%#0%.(DPLTNS9ZL:3ZY/@1R/:/-W;U_Q3T'-2!*6.]R6SLPBU
MB7&/\=XOL*>JUXGR [HS#7B^AXAX>_OR\OD!:"H3H.B90PHO^W7%PVO%_B)[
M+6@9&7,!M4LJ[2[Y$M@4?&&4F<I8&(7^8)(5TX_(MD1;/#274)U%@XS!X*+]
MG-.3_PY;]G7T2P*39W,&NNZA&SMY(\:6(>=[7C3Y-,UH D;DRU??@6??C,B7
M$?DRDLCL>+9L^X1;A!,[^MDX$(<?X3T .]%1D)2%$.)0MFW 94K1AN<R:BQK
MJ#F^#H>Y3 E]KS5\;0O*6$\8Q2B3.=81W2+ 1-?IZ""I+'5\\/[_X\08#F)]
MVESAAKZC/R <*%_08$Q803]89UH%3D"FP/XW6!I@\E_6(K_# /$B^@@&TVV4
M9LR-*6U&A#JPZ$ 3?BE2Y!&$5T*4%-I>.7L5GI%?F#Y':)TK-R!"#BP5@)>>
MDXZ!4K;B5GD:M)/<&K<IL<F0:0]S;S#"0NH8]FUBSPTP6S<4UF8)9G3.1+CE
MTZ)@8+=)[NY8'\*3!+LD9P9"Z;':3W$@[;_EO5TV+?LI+D"*?._2C97'Z?&1
M"D-5) R1"+:F4%U\FU;HUC'Y2U%Z^^+8FZ?[YSA2QL' H)"IT30(I@FG!''$
MO>)I2E/%VE78:!YDRRJ)$"C7?P?R:Y/(5*YX'$'J4OJ-)RU1M[,S>?HCX=/@
MX*B)P?:ON3RV]=1P6&1:(8ET'+J3A\7O;H8SN!VW3?C9)%WH9>G"P33<YMP;
MY_3B3BS<3-$8=MMAV"W+'G38[8>R^+CO<M$/+EF!=L>HG-8Z=%3IM97'P%)+
MM,]92X$)$Z#?(@^3JVDLO9<&>B+9(E2JRPXF-%'891N;X&F+LAGNG-*&%V:)
M$X?+TH\V[SM0%'H/WK5@RUXI'/FGRG6:/'<BP]8TFD2V2$,L-%1YT0K^]\<(
M>\IL/18.>@*9+E5HVZR$OBC$6UJ^)UHV[,,8":N<KH1]6Q1M8!U+B(DXY"Q_
M\DJJ)(D@ZNG9V>DH[W8H[Q:+!RWOWA2V$\A/DK5Z[]#9[)=]QSEF:,['1<),
M+Z:W@:E1R$S&S79%-"]A#: )9JC%-2$;K4V%P2*.N5W=)S*E*Y[]IDK<*@SC
MLE"-8&U8QCR_B,C$EA&;U2[]#)?7W]G>9_T#&D_L#D]LGC_H$_NR*.^B,G[T
M4U%\I(H:!;;OUVBY0A;DF6%9()X(@;7 GW!*?DF,8\HG5$,W,WFA3%ZHTA>R
MG1%(H\U4G6D-T?FWE^:<=9BFS$5G5WJ12SQU[,#I[EO[C*((_:6JL/73+68.
MN.5-4<18U"6]>\6$,/7.W *4RZ"QL3V6(*>QS%BG1S*_ .^C%?/$FC8(8$?
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M5H%H@N); 50K!Q9CL*E;P'AFX):SG@(!RQWFW#>8-.B@)V5)3C48! F%13Z
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M0OG7_[YZ]<K03G#-B.')1F()*T?,3U[]:_T/.(K3W^3$S>&:OE%MXU<M5"_
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MY])2X].8"#J5JIS.S#1YAIDS,F"[;3AM07LMP5Z#FS)H*:PV@3MFF51S=XO
M!\?*Z]^I_8 M\E(R[Q'80;'Z0G'13&J%T9<4R^[8KZ[QTF._N[WLU3'!&X(I
M5J")1%%J9!43M(J 0<CT.3Q&X.4?0IP>J#Q]G=1SC#/-L(B,O,68O+2]UP_*
MV<6#,*&FC>3MD)1%R@;Q?JD I<;$>I[<%,3T$/O-Q,TQ52BI#Z^Y(.</Q4%6
M3#]Z/V6NO.?'!K%#X*@%3QASVPLU ]99"$J&$19P9GM!5/P><"3[FF/ ZU"O
M[B=G&"P[>G+L]%_P&YVZU4XL78EJTN2+1)V\T_00.+_\]-*]G'A [(LEGT!)
MD+0056"&K/.U0+X/6A9JP@DBBSJ)M&57&S@D82$87" 06@M1XWR:@(/,5BS,
M5B1I[BH EINH*/GMT8F@FA+RXRVGK?>;:18153]N&O7WHTEQFQRW'DP*3TLE
M<6ILX,HJ.?-^46]3=F0 !9_9PY#^(43<[6%*N.<<MHB4^<4Y_'L5<J]F_:E?
M"KG0#'0L/M'U)N@Q'7XUC MB.PT4'U):6H"E0SC^62=BE,,"2/Y8\Q#NUR8+
MD;*)1\<DUL-AQDO@?&$U%:&KW90LJI#X=J37K_,,J8PTA6+4XMJ)%FH>WIA"
M_/$R6O74.>"9-U8J@[9&4^=KR8$#%0/7IG!D__W2>U(C=+XGB=2WF+"N4\IC
M7P"94[DNGDY1S]T("=KR1IWB6[CP$)>HDPS;9XZ%BX@F"<(PF<"BM0!^2@S7
MCT [M)#,7$"]C]"@)&N&Q#BZO0E2PY<%E=!D*WN%X[$2=2#+2@1Y4O,X-T%<
M*QVA$-XGUOS0IG%@G'Q@]H>B2JF6Z4,)@L'I<<Y()+R+7/27?X)Y%I?1'?(/
MP)5(A1XCD<#1BW]>@AW,G6GH+2?B3:I-+!58)G<2&<M]T=3<34#B A3L$'M*
M_5^;9)!@B!,(H<?PM(2JA9@)9$J=I(TUAEV$>3ICIH_0B>6_2F*M(R>BDI13
M'MP4A<FE*!7=HJ-V#9!I@NN,[2QTR1"4OV!2;GQV=!NE&=\'#H;AZ>.V5BW-
MA9"S:(&8]Q5?[2/YH]RL)*]Q5'<3+R9GQ2Z"MSU;-"RX&AX0K070-U R"B[@
MGZATAY<,KJ)# 6^7W%(.#H,1*GZ0 0DW[W"&#FQU^#F8[8?8V "O(VFZ5T?8
M-C<8;9>O9;L<:)3FVE0IHO#]("%):?Y 9O)>C9KGK0BS):_E$()3M&OBR[[Z
M]$J4%N@.D-#)/;Q"X00/1&4X04[62DXBVN:K71D-UR#^9)9RC!R3T\>F:I;#
MI J,%J6CKD<GYR\5M(Z-UI^Z=Q]OPLDCO&4SO(79<>W>IY5P-C]/+Y4]$B9$
M:KNCM/0B3=8X<DO8V[D,)]PC_BT:V*C%K(/K*=RVD6):?_QPC(30[O:6[<4$
MU[H#JI[=%E!.UCD+LHDKF8NHC^_1?1#-"'-18]B4WY=-"J>?TH,P_Q\?38[!
MF]RC\FMO$<<6%>#0\\Y2Q\DL(AIED YH6SM]4BRX2%<;]_1ZOX),L,I >L@>
M)<YB-^E6+BC]%=U$:5YQ;B@KL"4D,:8A.],"L3=4W[ZD1M6;&#H=2C7JD<F8
MOMA-+V;)#5B+LT02B'+G"EF\]JB-1A3-5T31G(THFA%%,Z)HAEX;9"S2F2)9
M?)E69*,VM70#ZBG#Y_YQK#Y:GCY3/;3#);84W%;#"5024Z.6T]C70Y7)*_HP
M%!\Z"9NQ+.[\M)_T+*@Q4YHEA-#4E!QCD#N5<4HP9V,;-O[ 7H&F/OR&>TAS
M('-#C<LQ6<>6.(ZMJ3Q4BKT7\>PC57-!Q7\PG_P:, E5FY?64:QYX5IP-J3$
M2&/JK":JU<Z10$X89DOYU!:TU6E@[G@I7B;QH97?DT66[M$B&R,A7R\2<J"A
MD#=%\&,3815P0G[3.TW9A\%5/=WK!AGDZ3#2N;*^+>4E$72&@B8GROZFI-A!
MB]7#9(8:ZO,^:S+MD4LY4O%&T.EL_8;4#^6!37-&1+9Y_D@K!F/1(-R!%IT;
MD'!QD; 8=R+(U@'J04:P@H%'^T\#>3<%C9!X[H^-/'/M][JJ#HOOL  ]07I,
MW22#)V5;?:W_X&0R>+(/]&B;M@=OBOR1$/@ZC,9[/=MOBAJ--%.18D^*R:OV
MT7_?FTK AK1L_5:G!JE-".#=V-ZA'0"2GD<FSF4J\RF7Q-'-U"TX=;C%4.04
M%?CW^J:&AS^'Q5KR8J4]B]7UP\>*_FTK^J</NJ+_9;+GM,0E8>,Q+,4:B! 3
MVH:A)/^E7=G*AV<9M3DW-L(Q0LG!9MC0G;RFE(^*LJ_U90FX!M$MF>L+2GN,
MG@X<G8+!A^Y"^,'<]'B?X5S/*H#YE&[<0PNG9.3#*S>2A.Y0V,4/6MA=2?A[
M[[CY=GRC(&E&>)FB0DKE3L0^T#A57U!*(AJDUP5CUHXFV?28%/3TW</#Y-.@
M%TO&Q3"3G0MI[R8D N0EP7=PQTP!%I73!@3G<&*N6G5 ;FDRH6E3;D%*DY'?
ME-SIAJ;I&#RJ5)[9G3!3_\Z-,$NMH'*17MZCZ6YR.Y@:K(4N5USS'CH_A+N8
MWC.+95!'GY)J:$*]%^X6/>$3;S>,OT/5+.2%N!9Q0CJ'@E1DVV%HC1DYJ?*>
M/A.$$E%1V\%',=C#18E#D!'0E-YSSY78MLA00/-*P>9-,_IO-4^72UV[&%<A
MG32U,<('FY0Z6V &:C2GMAR5?EVAASE/)RG^JY(B>,M"+M1AEI>49A)?J:PK
M[3MBVI]RB]"7:.7_4X)_3E/9;C\J>>7>9I\AACREK;S?D]6/$TN#$.R%A?UA
M%F;05;.4GKL51QZT_LYW6'#)=-?33-/F@2M![91YLJITKZR3(MWV]E;K]JSV
MKPWHK-E*(!P*T\,_CRA<@7QN^%?R"40&RP^CFOFW3B.1TEWV8L:OHM0,H&A:
M$@&-LU:QB:VY85+TRE;>(,(D:^"CCRMN]".O1AZ@;"5[-5\Q"YY'>11'8:"-
MHBUKAFN/A++\NJ>M<#I$@-P/. W7, W737F;[+&.PF6E7B0+4.UYW"SX%)B)
MHQ5 '"L^%0ZK+;Y2Q$_OZ4 QU@+="M+#VW95Z.TZ:G;@@%3TE.CFI2.6'HL"
M,=ET<YY F$W II?1R'9ME1@Y<EJEV=#M7)F_+2%T&+Q\]>;]98!4)LD=;5HK
M6Y:XV[%/0N_(.BT&"+<E16^#PMJH+(I-T4>.^/%T?=_(4-<)7TV/IFG1:;L-
MQ;C3 /5==OEUA:!+MT]91(@9+N[,OB$944<?DWQ(?3'PS:FV,7/@O?+&'H3F
M+:*JPAY2*#;Z="3315:P;1Q@(+Z$!9L'YCWZ;SLV0?KJTNO\? 10C "*L0G2
MCF?+$9 %!7E8'!KY%U09Z!-6$^#U+>?IM-<O%A'J-MQQ6ICVB7W["%^C."-"
M &E;B5HH)_B@H*!Q%%D1W[#9VW8ZW681Z+&8QMWD@FE/[Y;:X^]:63%#"N&\
MHDTGH"[5.8C2<EK"00VFH+>XBF;3%$B"4!1S=W;;&BW3\O.YFQ^L>^K8&0TS
M;#'U6TNMEHJ*+ZG$Y<&QDF%&6!,GBR(<<IBS_?.W3T/8N$.O#D;>U+%K_$P0
M)FC_?#[X>RJF^5"F-S=L)ES=FD*_'E<1#)<BN]79$EL)EXH;-YZ=/OJ'3QWJ
M9'(,S 9#0U)0''F-2MR)<CLOF(SOG\_6OP?' ?K?9C?#.N10-TS5_ARBXRUB
MTI^C)_YH#2">/,P&$)<O7KSZ\.KMF\N?@N=O__?JS>6;#T,M'_Y@N <W-H[M
MAW(3M91(N1'CIB;2$.ICH4_,5%Z:E-/&MIT;L18B0&"25<D=P7PZ)"G/QO3X
M'[W_QM4G)+R_X:;4STV'XKTFD%X,\)#W)<DQ)0.61\*$YE3_B^5UB.%R>%R=
MA&I$/9"6Q$E'=ELQ;?BTN+I_0O:,4@%_^6R<?6DAR==?"-5!9X_#X.P)AG;.
MGJKQ[NT:B:_!O7()8>.\RZ?,#D?+YV.KV[<10QUM7ZZ:"_7&G011562)0W 4
M"@T7]1[5@J=?&_(0B(N0%QM>1<W2_X]SA+0#\B;*^J[Y!U:%5\UB@3FR.*DC
MR?EHV-*4G-O6M$O9I4=G[&WTT\YTFJ^LJT^G.3F7VR6UMB'U*97=4\'8>*W2
MH^0 \TI35H> CB;[8P/.VK%&VYLZD^D0+(B%[Y&.,6S!I07#WWO[@VKL73*R
M THAO,*P6[IP<V+79E9,Z?L^RU"E^I3WH4M(29F<J ZR)$(/F9*PNNV[/*"P
MJXQ120G,A.^\=@*\G<FL<.=/CB;#E'#@)6YY_-V[X6_X[\>G/PS>^W@;IV(T
M6_X8?7I:V^Y #)=+4S:M/437(7$%Y0<">XETB93I2_R4F-;KH)5C(F\..^^*
M:7<YXB19><KK<E)9W05N*&[%/?6YMI($=4;8MI.(O"SS(/H#: 91B%:""&I%
M!DPB@"PMF1-24S98A#GQHJH?.65.BAI8_V"&-K#@^.8<!<GP "EZ:&[K388^
MQ)& \H,!U(3":'K?CZ#4G_].^N@MWFH"1PMWIGF&6E"W9F@&G6.-!%U>F?D*
M1"&WL%> IUK>YK9N-]#U@QY^98OU^,T63%Z(WP7[7R2Y$G*TW@SK]N3J(5Q,
M9TN'SB-L*_B*64475!:HY!TN/);-,8TIPS>_-H5@R70]6F6-M"A6N"5J2!$1
MB0E9KHC<".\+VI0L4N$PM+8;#<0A;9JY3]?7H?T[+Q.X(C<_3Y' UMDC[ON:
M%MW:PD)Z_#*39&N/L8"CS*8-\CL[SB&0[M*8&6)Q!T\P00( )12O"X'ET$^S
M=*:);K98]0FTER-0//A;+!Y(\4Z+0LBQ+XV(S%9K.0_X95SV"@.Z,71V T;-
M8VJ,.&:VOWYF^_&8V1XSVV-F>\>S94L1PF%/D!W!?CGNB'!A%K)V$UN&$KMN
M!3>$WQ?ENRMJ02>II WN,-!M@B.I$Q.4^%3'%#J,:N[1H_V#UZE=^E#I:Q<,
MVK%W\8JW%)-KG;K740W"?K_U'Z\$\W=KZT"+*1:!(WA?F]$PT3_:11%6FB'9
M"!A0AM\;O&9;H8#)KH68UJX;X,])502FCM7YV%2-:TPSRD&.U&636,0]@Q9,
M+>DLXBAFL4@9ID$0[/8%3@5%+N8F7+N(/B86M^V >;%KC+%5L4^EF-_3M)PV
M"ZSHQ7K NWF2M]\@;9.RF@KV,J0W T&6)5%L@K<S WE=@C5O :Z&LW< @DO3
M;DO:[[L +7(WIV MB^[:*.%V*XD>R_O("6!>*TSFR5',MO63H]GQL< T.( B
M,6Z);O;E?IRZBXF)040F!81#+,"?*97EEDH<$F9#H"7D1\^:,D^K>4". <S8
M76X8S5HET?9,>S/7=Z3=[>OLG;2S'2*ZEFZ=M%8D$97[^]WN2.5L=CM3(_:=
M>G*X!J8H%'+LP:VZ=J=BSQ%A=>R%Q'-W%XQUD/MM*L!"ZP$/A374P\Q!R=4-
M+<%=1,7W&ML8*)CJDBKU'Y<=6#J?G<?<8R*S39I 8+6B3&X*DIC=D*RP%KCY
M8)LP&5H])F!$E 6JFT #3IVF63X-"$+I4M"4-LZ0&LY&BG88WD,<U#8#&9,D
M8S6PVZ70BHGW5*Y";$5E@5&[.!@V.G_7[%I\Z3:,Q/N46^^4YI=.NHEEZQ*I
M*-M<8\H%1\Y5UA)P0"Y>8'XP"=L-C5._*^=)@U%[;?5@C"PGQLP@"F\X;8#(
M<9^H5E/,:R0PHSP8UV9%;MPA8J8+U*/<M-#A45[JF:B%=E]35*42_6$#'[SA
MM%B2+B98 T?!];>#RB&OBAE6:%=;_H#;-1@[<;ANO:>19UO%6*5&RD->R)@C
M&\>B%6%]A78T@V+UR).+8?O; 08X)I<RFKN]TK8"&TAR0O=A+W[+A]M+X&C4
MD3O4D<F#UI$_<S)P(!&XSSB*ZV;8=FJNPTY-T*1<GVOS0Z\JGZLQN<X5O].^
M0,91AI_(+SJ7A]ZQ=WH>M ^_TP5.A8 M6K5?+A9-+J7*IH"53%[K[U1.L32V
MT3'H!WO&W8:5=)JEZW&9=/M7GCX=EAQM@J/:K8WUY"N%B_V6,49R#@Q2^B:Y
M*R$-?Z/J, OI#V[W=YO.C)+ZRR7U[$%+ZH%->D!D1P=BDIJ?K4&WK#?4F=F;
MS:@=\,%LL$A#1N245A.)8;>3MW#5V C!^.I'Y/S)",$8(1@C!&/'L]6?=]#6
ME%X8N\F-NN%TQSS)XM!F8A4I"*^4Q%MK-.L?8"W^31)RLTU")"]32ULP)+W7
MJA56<.W:%GJ$5:G8@L%Y,P$^2_[9(@LYQ^35O:3=2J1V&<.FQD3MNHBS;Q\?
MQ9R/I);SFK_J:[#!=3D^)R"X7-K(C?/FJ?\2&CQC;D,W/=6/-%=F=TJ\E[S$
M]&\,],HC:-5ODZQ8<JE17RK^LY=P2\L X3]9.JUYA'=%D\7F,X=ET &K2Z62
MAK[689)=)"S?^O.2HM[H]I E131S),EJZ6Y"S!&PX?-:X+-M',"Z0H.>5#[Y
MLT,+#6^0X.XG1#/%^THTD QI!Z]6*QGKY[#7WO_WE-'VUTJ*MS:LE8@U["0L
M_8K'MHR#]7"TP9:;4R,F2C.PZPXMF] 3B^\Y#(-'Z#,\+)M%OL>#UB0#=F>$
MC$&?W05];AYVT,?4B?%A?"A!($)KH";A+CQ2\0.2BXT(,;-$G1A<G@\,X2!R
M"X/2EU;K5ND^1FMT3>+L<VPZ9ZBMWD 6,LAOAR\_CVZQ7B?)NZ]0&ZKN\:#O
M\*#/'_1!?VZ\Q@%['C7<(:0FMBCS#5R*APRK\\6'0X_NH!W1_@JXPAI&YLS3
M'<35/V*%SZ:KR_7*WYMRU#4KRQ01?06C\6<]JF4:M6[?'RD6:8RNIFU Q(@\
MQA)LDKT]ZV=*4]9#&<( )-/<.$J_XAWYRRU"'D)$3ENLH/]>&)IOVJ1.'X+!
M[3>H*]!B-=\9XG'J8=,A&<=-\PM\6,4I[S,WA,'TP)Z5/-S(QA2:]K>[[\ J
M![@0+=]QV=.=@*,I,^.H226WAF PO6[B)[W1D2XRNZ9@TY G^P4Q",>-S5=?
MPY'E17<JCJFRBJJR**)&,S8 V^XK2Z#M:,J'"4_ 6[E3[B'MP(3$QO"';%F%
MP+N+#(U^'!D-8 O(?Q=Y[\YNNQ"X>VK:SPWQ9]C;==9I"UB8H]RRK$Q-.>YC
M:3%K>A\2V0I-:R4W3K61E-N#;9I@7(&+HODV%&\I"(ZP+-$XI2-X?*'GP=4!
MH.^)I7;-Y&]+"]%W/L:,W-?/R#T=,W)C1F[,R.UXMOP2(Q27;3X?$X!'4Q],
MU^6\R!.P:-F\I3)HT[!"4&7'JA\,?QNV_HD:KC2S(%>]<R_A8;Z)2.5+!+AG
MX'"$@ZNKG!1!Y=ZR, PTI7#,:!Y!*9S<4L'/J-$#GZF6Z(G3_C@..DU.T9JF
MB".;_1XCT7"5C[&=?FGB&S7:O"RE*>(AB]DKXO$O!8W;":U+@!NT\* 99 LV
M?<RS:=7JV?BYP3GBPUT<N8RPS_-K98S<W3<8A>)P\N!F&V,].XSUI \ZUF/Z
M-AT(;5LW?#LM"CAMZ&VU^9A1_O963\,!E!YB;@,QU]N<J1/*?HGM*];;5$Q\
M8]-"S'ARFWJ!F3Y3ZQN"U?.B2CQOO7+IHORN8%WR(SKM="^BFM3255!:3;)%
M>ZI6.RJ41:H,BB K4'8[PDUG>KAKTV 0OE7'J4M$[CP6@<+[!EX]$@<GAD/W
M6I3.+CE,#^R33!OZXJ"(+JNJ%,Y!<^$%182,F[W>HM8F'3"S,F4"-]#+^+F3
MQ"/TC#X)"^C B[0FA)3RL$4B<\GN9N7,[J;6=K2+S6N:!77[6QVWSX &94()
MR5CV,IDR;[;D_BXM&6X&Y"SK$I29 (-+3A8*:H;&(="7%C^>1Q[GT,5U-W+8
MFH'2OG2?"E7RFS7,97B<XC*Z@UTD:>&-M&6C*MV=*OWE0:O2JZC,B2[)F.W[
M[G7>$UGJ(?>CX*0(3X0D(6:&XL 8AX<C(@IK!69Q%E/,BOT@5Q/C^>"7MPZ&
MY =R[)4CXC\"3P(TVC&U2> &@&I*\U%C N7Z+LEN\83E]1S/*^S[7-L BX-0
M8JP]K:9P4I5GN=7?B,/%](Q-.2(7)(&=X2L)"_J,@H:$_>PH,LF-'J8MSOT\
M_6XPCC_*C!W*C(\/6F;\Q'2D%^#WH]EB5#FKZ+W*#]SD7;ME :K2(?JLW(Z6
MZWMT"27NY+@K@4IZ>?9I/R;)TI%!F+6"*S =A!W9$"I!=EU"BAY^4V(<$+YR
MC!HZNFQO4"$.9N@4HJO/Q?"]G/1V]W(]MJZ(&(_L#H]L]J"/[ =MSDZZ[\"<
M9>Y&2 =)3VJHW%C"B\7(R35]ZO4(&6]NW/N[V_N+![WW7S1)\"*%R4_V'2=R
M&Q-AX?DF@G_1,P:OT8HJ,>^)@1/'#08XY#T%<4P V6;:#L@,P1V&:4+0L<1J
MC$UP(@I'LRON=1I!@YW,6J,D;=\D"@ E.3.!2&C>=  --8Z=X^VR8-)4*3'*
MP[/%K/?#\AZ_@"ASOAE%MV[3LFZ8K/NSH#&C4MVA8,D?M&!Y[_2PU9#D/Z.R
M1.S5 0&*G226L,01FLU#=74!40;UYEYGC>6H [AB74Z80?A4272P\<B(T?CJ
M6^#\FQ&C,6(T1HS&KHGK0?#-+,["BR<:>$#9HQ;NC%IH1_R\<E2P3P@@N:ZA
M7XEF6B-(#D%)1.:V&BSDWFPMF<X]6^BKEO3NJR&4SPB(3J.*I-UZY9/7Q?1[
M["^^K+F(F[#5V%\QHUJT+A"RQ2UH3<'-X S;\-TA0V8 ]K'3 I+ L7!D:S8[
M.]B-_GQ6:GARZ<TVK*0I+)VL79(^9+(3>7(R7;VK=I]E("I%7 :I\=W\#CU:
MFZD#-V![M%[0!_<HKH>[!SK GLY+\LN/]$R[M*:+!VU-OV [$WW#"O?XAS*]
MN>%\R]6M'I[J(G@.AYJSJ4FUS]8;GHGMM'KJ*5.P&1S- O58V\;1'8X.]":%
M!FX94L>O9P/GZ[>T"/?:'_U/?SJZ//Z3C\?K ?C/DT&$GJ3RAS&-KA[C.@18
M]Q9#2)N)E;  189M9*AXVBDLF7EX''L_-SG1PN1UF4E-:]:CZ!CUW]$/Q\<A
M*M!%$G$B,!KLKA?""J73CTGI3P3\O&'6</<V'?)=J[M;Q0\;L:%.0\0]'N-6
M!_L]'(RO9MK_W@_^#][![X.8<JC#Z]GMM>SFD]9N_>UW_F[9KN:W?[G$7YOK
MX$_;$]L81K,TCQA1Y\9'Z:FF)*O3Z1,I0=*BJ;*5G/SU+[!V^,<$/R:K$4W]
ML.6.7, -]K]C'O*):#OS^SX4S[<Z% %5*>9U>\M\AUNJUV'=O*M=Y>A^;BAZ
MN28XB0TIKZO17H&B",Y/3L]Q2W][<GI&+,MF3*5T[D'PN[J:39ET;_%=^Z>N
M*P*>6A;!+%B XBR8HM.8$OIUB:8FU]#B(PI&I\;!_]_>MS:WC5W9?O;]%:BI
MS"VQ+EIM2>ZV8^>F2M:CHXPMNRQU,JG45 H$0 IM$&  4&K=7W_WZ[SPH"B+
M$D$9^3#3%DG@O,]^K+T69V$4[C0(X4J,R/2BX;VPJS%/]= <AHC[I3=?H))(
M4$0PA?FNM_?JU4A ^Z4Y!>JDPC4[P9T3FP?"Y#_LW! T'UQD:/+SO6M[M?,,
MR3,!1OU^\C:W^E@]8&U>RJVDHS6*]$['K7#WIE3<!,>>%XSS:ZP:AXLPL<E'
MK"Q?%+/2LO+="-/;Q17'548KGY/69AY)OI;.%O%=K0!1ZRSH,B&B$^" RIAK
MJP4$%(15SMIJ;GD!PB:DQ,!7/ZH2@DF6"<Q'H/U2>K1E7:ABHCN>.<LC*14.
MK+)K?TVQHX;:%CATJKS-">4](,ZZ0DP5WOM^U(P;$F5^7.#(H2&&TH23!AA+
M\],H"F3]@R7! 5Y>]@+A()]\;<;"C"Z1P3=NU4>-X] F?AF_4R[I3^R2FHJC
M#5P\FBT-P\-'(\>&T6P"9NQUQ4:]%+Z-+O3R2E>(**-=V27NAK<@>GV<-Q-"
MR#<Y53H@3=)UD2[(:#TD;;QT)4J]S"Z1Y4V*CU*+JI'#916K)%8!D:*?$^F\
M6F426G"I55S!PA>L3FIE8%P&! ILXBO@,%P(ND9E 12KB(1ZS-$A2'0J^J*C
M ;Z(5J.&CNN10MX\6&[$,M(^3B-]YF:PA*Q1:_WV)J.J-1-QP @\(D;@]8 1
M&# "#QO2Y^S"W2'[6>.Y,22]J4-Z8_/M3/(TS6^X@JC]/A.N<>MJN@GLXE8\
MQJ,DDK)/MC*,D=+B95A&AWW!DX.%W(S8H?;;BGVANV\LIX@9>UO2?2V?-N33
M[$=V< ;<W2N&KZ)-C25>$M2J=9$NXJ@.C;#<O+N[%A1<XFDSRC;NI2$_O6I^
M>K[5^>D/\31(O4^LB+[1S+/WZ1M3S'7WD]( '0=13>#,\-59\0WQ>>OL(?9.
M;4]2PNZ<Y(H<#DQUL;7AD1:C'U?XWRU5@+&U+$;?&[.:T.N"">C2&#UF;?DJ
M*;F4YM%2MO\ESR,XE#$<$>(//GSX[&N.!AE>6XCH@GP][S,XY/" ]_ET6GH[
MOUZ,^(=(U9(BK21F:"2&?-OQ.%\0MCR$5@<5YI:"0"T!(,L/K<>"MCX.5"TA
M"-KUSF "DWBA R8RCT*.88CRN4 W"27Q4>IPFHF$.Y3$[E6$$#85;\3"(^88
M42N*:@*$<\B95GG2'&.*E=;7U?0>!:;_<T8*Z+$V#*MJ2?);S/!2<&R.2ZE(
M'&9+6.M8-Z7XX^'/[7O9!84U917X/%"O?QQ$6)WIB:]E>GV[Q[H[5'"M\>K]
M]U9?O;2#2MB=O-N<FWB391:7M? @<987<!!RY J/B6.X_&+O8UX4<&4Y-XO#
M_N,[IYEGMB,<7/QORU3G6R*S[F2[1L,->O.[W#O/IOUJOY_G([]A 5 #513Z
MKM*II(B[=*1ID'3N5S]9-96QK*8VC%[47IJ%W"E6F?2,0J]P*!+RS6GO #-=
MXUE2;/59 HL1TR=PB.#*V.3I,5CQW96O$G6G7.Y_??[X"Q^=[+=',8;Q.0G+
M)&ETCD$O0L)B",@"\X70MIQ2=L+A(@.K(!F.+62DONZD=&ZW@/QVHGM4Z.$E
MIPR[M=K[3YK[[>:;U' 'M[-<(T$Y>)M(3=@VVA<MKE8V?*4I<!SH IND4LF[
MLGTBNYGV.]F\(W?&24?(*F%<MAP0S&M9O"P>*!=4@P2ON<"#M,QEE=>7B>)G
MU1>EC)E]1 BYO$5 9N!#II*;.,:N>;_@^.M8IB$L709KL'*E+D2Q&\Y8YS-U
M] :1Q]0"2%G?-,BEMIG=;6&.J)'SJ<T'9]&,C25$6F=Q?6A-DFV.>=]:8JW3
M\WC.P>X7<*U[GM?7S#1X[$%A+1"K".1Y7^&K(:'<VSK^/0X7</P,:=SO(HW[
M9DCC#FG<(8W;U6VCB\672,,\0<IB(8\5H VT(:ENEQGJQ&O!9^ZM!B4&507G
M./^"!*%JN,+9'.R/V-*W%G,(CD"A3UX@E664SRW;\7T>%$0T>4QG9EXTD(W!
MHKK*"UJ\8B[C\:]X=]S0D M[E/@,XH<6,]=XNXL)Z$YA,?+5+'I<JYRMN[I]
MI,!7JD_<)FWLH7>T2"EVIBA*."\NG>VH@[<N1Y_+PZVI8P:A*BY548# [A,1
M$EC,QF!AXVK B>1V59P)(D]EAEI&Q'J]*&)3D_TY+DJ*T>7Z/JZ//W$9MV@D
M&KERKF9/U@I8[*55,$3?5HV^E5L=?:M5J'RZR51=S#OO*$W0SU.?J@]ZPZ,D
M\L2E&R$1ZG&?,2E*CD! *R8,E@8W.@6),0D,'+GDG[6AR6\R%<UBV0Q5MBQ_
M$]AYR(.F.-!(YX-EZ,HV?4:!JG:?P$.D?(U[M=KJO7J67<-]03?5!WVQ]V8W
M&H6&A-KITU5:*2%A$4E7U/ZE2<N)7:6>0UDZ8@QORCLJBQ"+<[,,H^*EUE]F
M$(C])"5-R!L3@Z])E 1%PCA +>B!T>A,&DV#&\KO37S2&GGU\(&!>[U;<['5
M6Y/)J7%1)-=)K\@&-2<2*J" S4Q.2WK+:17U+]^61F'-& [@TAT7H/(GRHJ.
MG<0',@&'DJ7BD#FIB2@==)C9<9(JCX&(M+)DOD@=KV9>) UOI*8HJF+[2D
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MF91O<=6Z_? ;O5"%ZU;@F,U6!BEB@" -;KCFW\ 493C@D]+]B*QS]'SA '
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MMX'SM9*=YX2W;?.6#=J6LT0"4KZ.&<D.-HJ@I5MAV4=7NQ]A<=_RK]N(+FO
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M1'@_&!NPAV;\/N9<QF=AQ8RB?X _)Y6OU.3Y' GCF&S0H&#2#F0=@]>CZG2
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M%/JQ%!Z87K]]V\L"\Q<_EC_:A*$O/,][\=W.THOS8!:W$J@^?5M6HM1YGK-
M*8:WGG=TE<03[S3)P(#"M,LGYG?HYPK][@[.9Q/EZ9&!T+FPOY-N/_UA<^GX
MHPYY@-3N&OT[2KV$6"UH@O:"JL]T,:=O%2QK?'>$6&YX"E8 4%V89'4Z+<!A
M#P^=Z^-._>O)Z>G)E[.3"U+AZP\\H]-:&M;:MIA]Z"+]V$<?"3RD8RQ4C;P/
MMUFPF%Z]V)9K>BW>D-OW#3I$WJ8W^1.[/Q^#+)BB57(L5':;'/M>$)YN\RD[
M=''HXM#%H8M#%X<N#EW\KKNX#M32RT>#E56Y]VD>9V!^%E_CRKL(TMC$Q;XW
M@%E/<$(#].KQH%=]W.-KCHZ=_/=?SMZ?77J'VW?.?3/4[.+BU\/SHQ/O_-/E
MV=')TW9\<\&#?QX'55P_I)]GG.2O6")2(*#/"D4_ZQ[_M/\2;F6X4?.[=/>>
M5;=;,FM[+U_N[P\A_VV?V<.JRMYZ__R7_M^F3ZYMGM->(;V_H+8*E4(EPL\M
MP.QNU\(;Q]4-<G#6]>R]G9X2(@O(?//%WR.")C@78F\'C0 3?1BRB(K,&:,!
M"S*\\O;W?<_;?[G_2BH 51&!($"$H$2*;[E^4+-+VQ6B5$YP5I8+ OZ?,YDP
ME@J609645!M9@X9(H>WW8J4>"[7AL35H]?':L<0ZYHL"/Z0BS3YFB.LR34A\
M8]7;/_T C]YZ_VK_W_>RQ/1R.IQA\8ZW$_][$:2:.2ROX!]X_Y3>YP*7&U;Q
M$A$H2T5U,]0]MX%Z\8<^[J@7+UYL$!3XR/B._DS^^6(V9I6T*+BE6KPRUB)Y
M21Z]_=9)>++%\=QGZ)1 HY%B8!YFIU>S\R$8)J>WDW,15U7*KB4:G#OE"+ED
MF/.$B;^QNAAE72[_SSXJ=\BWOY^KO^\K]-G?_!N-T9RF>5Z(^;N3H""W2 80
MEP[MD#_L[;Y\2:7KJ(9&E#8.*152UUCT5N3;^\+RI#Y33#WPD*LXU0)9]%TC
MH%/FR*>4E&$1XYH"!^8/Y,+@:8JE]L4CQ[K[LRN/\ADQ>/6T8-3Z7P^WZ;,O
MCKR?5__=E0<^^_GO;2'YBV6FY;.?%JZ5^'Z[KVH6_C0N_KS)X'[+V?#<(6J;
M1-D<_K"YR=[[/NC7>M:S-T/'!M3FLT%MKO$@7;?8<G@51PO$1VR<[W2;03']
MG6!)<W]FBN"-C\(V3W*OSJK^QJ8>U?^S\#);,1CK"-1=Q9D'Y[0IS'[N/6XA
M1AMV]'/>T0Y8[UE#D7O#<C$@H+=]*7U,PJL@3KV/P30HBKP_:^FY1\)ZXJ.N
MYO;_Z<=Q'MW^^7_]Z<>K:I;^^?\#4$L#!!0    ( /.!=E@G\DC68 @  !,]
M   .    86-E="UE>#5?,2YH=&WM6^MOVS80_[S]%=RZ#2E@.[;S6&M[!?H<
MBK5KD 3;OE+2R>)&D1H?<;R_?G>49,F.TW9=TCBN P2M^#C>'7]W/!XOD\SE
M\LG7;)(!3_!?-G'"27CR\H_N46\PV2^_L'^_&C")=#)GULTE_/1MSLU4J!'C
MWNEO1%YHX[ARXX(GB5#3$7M47(Z_#503<5%/JGJ[3A>C?N](J'$N5#<#,<W<
M:("?D;[L6O$/48BT2<!TL07I3(J:1*J5HR$P&O0+-R[9* F.0U_*<R'GHW.1
M@V6_PHR=ZIRK>F"DG=,YCG5PZ;I<BJD:24@=K4'3ZV5FF7#0M06/8508Z,X,
M+\8K:[]W.5QK)A*7C5+ANC&.!$6+_/!@<-P?3_9I[I/)?H&_J)^@ITT3<7A3
M(MZ%<+&6VHP>],//^+9$_6KQ\Y:;.&/#88<-^\/#.Q9^JW=VJX7[/+!]FH@8
M''LF=(>]5G&O%OKS<\*^"'T/#@;L!3<NU]YE[,P9 -=A!R9AKZ369J?^VY7R
MF;9.JPY[RZWE<>8M.&=9?S@8''^YJM^YT?]_^I_"Z*M/1% 0((%8&^Z$5B.O
M,-B50L%-,'8&L3?""1Q\"E-A'1A(6%BB:BA715?$'>0XB>''*VUR=M8]^"*!
M&9@2J"'E1L>]X^,?OU^-]N\W5G\'EO$+8#QV" 5N6:R]LB"9TVRN/1,*6Y2"
M..!B)O"<PF;#4H&@G#*=,OX1T&%[2)EC:X*+:,.L+PH91D'282X#]L.#RV%_
M$(_7TRI[D_%#6I=(*%8&UH.C$%@/2\Z(4 OC7"7LY66<<34%]ESGN;"6R.ZU
M%VS:FT4*;ZS'6RLI887FT]B1T(/'!P<=UA)JB>;R^ 7=#C,@43+46T78M*5%
MLM2FTQ0,C8GF;#4@PR79"Z0QXP;^SQ$U*V_6D9;)C9Y9GQ^_Z"B+RE=>V=>"
MJWE+^:A?7Y#FOSOJ]SO]\C<@6,T1Y'DDU&(C;+.#U;:X>8$?MH!8I (W'-L,
M"-5CY]AYC07,$"#HRR4G-PNXKVA%:&NXL42QA<B YSE[7(*YA_00 Z!B8,*R
MG"= ;)/9Z4(HFB Q5$&GG7"RVA53(-@+%4N?E!;]\C(3D7#LJ#>H<;>>WQYC
MZ Z0661:(J,!A2Y#%AI[Y7*5AS4>@I:P7)()3C&F#;HHC";E.=^FMKQE)\V0
ML\60:TV_OE.WU$D;WG#0TF_;H$^]!'8X/-R+'E9'WU431TW0MJYEJ#1B'%?I
MLFVO;3X:N U:<$-MV0Q5;%<\1FAK9*U MP3BQV/RSGF.\F#<&O_5804W[()+
M#^R[?@^I#UB!X@3Z;*_MX,(NXY1F@5A?A,._8OI:0) :2N8","(HO7X:)A/2
M+/J0FDJ]YZ0EA9Z1<-@)HUH;0#YL%1P1N!F 6M)?(.YQHUM4>YMW3._"DML,
M2PQ<")A!A81$QY[P4A[MP2^&=KA$ZHWSQO.1_-ZLHI$0R!"L!;J@P@C$-EGE
ME#QQL-_*G>'MCZ7:H/.(0.I9CS4\2$%A"CD6O*@S4GL!0?>,G&0JXK!TAWQ3
M#,:5+>714?A(BI@L1L2"R\!Y"!R0A9R3 PW#4HR_Z!O)<;GP+.LY6[M.6* B
MUK*BG<'<MKR!WXVP&0RVR<\6VC91R[40JHV#6^OS$,YP5QZ$C;/'P]-C%\Y#
MEXV6@^%(<[[ W[Y$*O:B'R?H$I'2AR.+(O=Y-8E[-!R#LB4K9V1SKD6:FX28
M3H3! U<CD%E8-O%RWB9 !Z! LX%:PC4S<56<6QD1A4B,8C4<LG3DOJUX/"$>
MFX.1/$M0AM(,+L(])L;0P):-,?>D7:*C?!ZAS!0_-NQ59SLVMH]=QB^XD#S"
MP(.427KE%-RM1 S(<0085EG;:+)9!;\4!BS5IE3;%)C*,72,EK:+9B[)]_G]
MP/VU"T/!=PV?5$MLIZ '?78-G5?>>32!IW2B8/P5,/.ZVM0:22.\\SX,)'@]
M[#^ ?^]3P;\('1<@J[[/UD2=M0#+Z*? ^#T4,(+E,5Z[DM"WB+:7E%'>;6,0
MA5L3%M,G;H\5&'Q7-S?<>XKT,BXE&IZ[:@=-J$NW,SKT2W8>5E93<)%\B+5/
M?<^XH+,VYK)",EY?P+2 ^:C7/^RW?@8WG?G=]F#O_'J#I/NO% AZ.J)*BZSS
M'^QG4(@?B<AJ4@!O^.P>ACPW5C2P4E:12KCLEJZ!<LFXFSY7XT380O+YB'KK
MNHR%*.N*+_[T%F/->;UPF-C% /C^5&7<6$RY:9(]V@GVT74TF6G*C:;0C3!H
M_:O+4PQ<1US.^-QN<UW2UEK /9;L;HLZME?B:VNNME3>$W1G=_@$,]QYAYUD
MFRG9U1K:;;]+/>.V?"0KDQ<&IAJ#DY#7H#O32OIC->L74H(1O<2LIAY"VMH7
M]*;_GN0')<GQ!H_W<>P1"9(HDU(=EGJ)7^&63A.45MQ:O.%34NPNZPS9!MZZ
MMRQ#OB&6<4X/V37P\;_E4V;JC1(V*],+5/"2AO*4J'XYKI(.K;=D*OI0#*I'
M]:9_.:?WW!M#R>-3H+^ 6-3"/.K^<J4(9%UF;GEZJXBA3)0)2L/5I0]E6MTT
M)0/J@V_\E ^/YB$)!TV92U/3X]JZJM[YU\N]+&8H/7!MYHC $G=->K!NJ4H;
M4H'Z$95/,H$>,OM:T4M=8 O'5 P'=Y;HD"GD24[LT*3*QU7RT]/85)N0<2S
M6)R*VM,6%F*CC ;^]J(I@CNKJAA^7.0\5RI_RM2Z\;(J+T+_ZF60TI85(8'.
M/4Q!W;Y/.=Q&I_(;(,"<H<.2RN)L9P,UL=OZ6Q%_W^ZSG]^]>_'[ZU_9R>F[
MY^<O3]F;-R<;J(\= &Y%_/=L_AT$LKM7@"_WQKQ[!;CI5X#)/OU-\Y.O)_OA
MCZ'_!5!+ 0(4 Q0    ( /.!=E@IPNL1'1<  &&\   1              "
M 0    !A8V5T+3(P,C0P,S(R+FAT;5!+ 0(4 Q0    ( /.!=ECLT<BWIP@
M ,QA   1              "  4P7  !A8V5T+3(P,C0P,S(R+GAS9%!+ 0(4
M Q0    ( /.!=EAUX?RCV:X  'I.!0 .              "  2(@  !A8V5T
M+65X,5\Q+FAT;5!+ 0(4 Q0    ( /.!=E@G\DC68 @  !,]   .
M      "  2?/  !A8V5T+65X-5\Q+FAT;5!+!08     !  $ /8   "SUP
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>acet-20240322_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acet-20240322.xsd" xlink:type="simple"/>
    <context id="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_da0d9fe3-cf8d-48aa-8a90-24c87e1fe408">0001720580</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_09cf4c6a-fcf1-4718-a0fe-dba5cf7ce909">false</dei:AmendmentFlag>
    <dei:SecurityExchangeName
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_85ae9203-5b14-43af-88bc-ee17b61c1993">NONE</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_68b28bb0-fb15-4548-b8a0-314b37d41e8b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_dba60b6f-0145-452c-9b32-44597aaf0c01">2024-03-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_2de8f9cc-9a1c-46c5-89c4-3e9512c72f38">Adicet Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_4fd3161d-fd49-43d4-a040-23e0a0dd012a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_738ce428-b8a9-468a-a430-dd6ce23c8775">001-38359</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_82a73381-9dd4-4d15-8d70-736c561abbb9">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_70ae38c6-b915-4949-82a7-c5e23d58ff01">131 Dartmouth Street, Floor 3</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_2397e0ee-3d03-4bca-a967-6abf6d388bd5">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_b2cb106d-0075-4223-8615-9db85a8335cd">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_895dffb2-aaee-4435-998c-fe255216fb57">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_e80cce5a-35c6-4a11-8d7e-0deb6e3d2db4">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_712d8990-4cd5-42b2-ac40-2d58eeafbd58">503-9095</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_c47a0e7a-e634-43c7-8cd5-8085e715d768">Not applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_0d0492de-75e6-483e-89f7-d74397cf0d80">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_3e1e1710-307f-4eb6-8591-e3de0fcf8b4d">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_20dccd33-303f-45eb-a593-a488cdba83f7">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_2623bc65-696e-4b4c-9574-99be5485d795">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_b901163e-fd9d-43fa-931b-d41b4fcd4c8d">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_524053c3-795c-466f-a1c9-80cd81ae627f">ACET</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_294a37a8-12f6-4ccd-8f7d-45c97a211ad0"
      id="F_3808d418-fdf4-4609-9592-44ead2f873b7">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
